EP4245766A2 - Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides - Google Patents

Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides Download PDF

Info

Publication number
EP4245766A2
EP4245766A2 EP23172637.3A EP23172637A EP4245766A2 EP 4245766 A2 EP4245766 A2 EP 4245766A2 EP 23172637 A EP23172637 A EP 23172637A EP 4245766 A2 EP4245766 A2 EP 4245766A2
Authority
EP
European Patent Office
Prior art keywords
antibodies
antibody
hccf
reduction
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23172637.3A
Other languages
German (de)
English (en)
Other versions
EP4245766A9 (fr
EP4245766A3 (fr
Inventor
Kao YUNH-HSIANG
Melody Trexher Schmidt
Michael W LAIRD
Rita L Wong
Daniel P HEWITT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4245766(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP4245766A2 publication Critical patent/EP4245766A2/fr
Publication of EP4245766A3 publication Critical patent/EP4245766A3/fr
Publication of EP4245766A9 publication Critical patent/EP4245766A9/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Definitions

  • the invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides.
  • the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
  • recombinant proteins are produced by cell culture, using either eukaryotic cells, such as mammalian cells, or prokaryotic cells, such as bacterial cells, engineered to produce the protein of interest by insertion of a recombinant plasmid containing the nucleic acid encoding the desired protein.
  • eukaryotic cells such as mammalian cells
  • prokaryotic cells such as bacterial cells
  • the conformation of the protein including its tertiary structure, must be maintained during its purification and isolation, and the protein's multiple functional groups must be protected from degradation.
  • Mammalian cells have become the dominant system for the production of mammalian proteins for clinical applications, primarily due to their ability to produce properly folded and assembled heterologous proteins, and their capacity for post-translational modifications.
  • CIIO Chinese hamster ovary
  • a small number of transformed recombinant host cells are allowed to grow in culture for several days (see, e.g ., Figure 23 ). Once the cells have undergone several rounds of replication, they are transferred to a larger container where they are prepared to undergo fermentation.
  • the media in which the cells are grown and the levels of oxygen, nitrogen and carbon dioxide that exist during the production cycle may have a significant impact on the production process. Growth parameters are determined specifically for each cell line and these parameters are measured frequently to assure optimal growth and production conditions.
  • the recombinant protein can be harvested.
  • the cells are engineered to secrete the polypeptide into the cell culture media, so the first step in the purification process is to separate the cells from the media.
  • harvesting includes centrifugation and filtration to produce a Harvested Cell Culture Fluid (HCCF).
  • HCCF Harvested Cell Culture Fluid
  • the media is then subjected to several additional purification steps that remove any cellular debris, unwanted proteins, salts, minerals or other undesirable elements.
  • the recombinant protein is highly pure and is suitable for human therapeutic use.
  • the instant invention generally relates to a method for preventing reduction of a disulfide bond in a polypeptide expressed in a recombinant host cell, comprising supplementing the pre-harvest or harvested culture fluid of the recombinant host cell with an inhibitor of thioredoxin or a thioredoxin-like protein.
  • the thioredoxin inhibitor is added to the pre-harvest culture fluid.
  • the thioredoxin inhibitor is added to the harvested culture fluid.
  • the thioredoxin inhibitor is a direct inhibitor of thioredoxin.
  • the thioredoxin inhibitor may, for example, be an alkyl-2-imidazolyl disulfide or a naphthoquinone spiroketal derivative.
  • the thioredoxin inhibitor is a specific inhibitor of thioredoxin reductase.
  • the thioredoxin inhibitor is a gold complex, where the gold complex may, for example, be aurothioglucose (ATG) or aurothiomalate (ATM). While the effective inhibitory concentration may vary, it typically is between about 0.1 mM and 1 mM. Similarly, the minimum effective inhibitory concentration varies depending on the nature of the polypeptide and overall circumstances, and is typically reached when the ATG or ATG concentration is at least about four-times of thioreduxin concentration in the pre-harvest or harvested culture fluid.
  • ATG aurothioglucose
  • ATM aurothiomalate
  • the thioredoxin inhibitor is a metal ion, where the metal ion, without limitation, may be selected from the group consisting of Hg 2+ , Cu 2+ , Zn 2+ , Co 2+ , and Mn 2+ .
  • the effective inhibitory concentration generally is between about 5 ⁇ M and about 100 ⁇ M, or between about 10 ⁇ M and about 80 ⁇ M, or between about 15 ⁇ M and about 50 ⁇ M.
  • the minimum inhibitory concentration of cupric sulfate also varies, but typically is reached when cupric sulfate is added at a concentration at least about two-times of thioredoxin concentration in the pre-harves or harvested culture fluid.
  • the thioredoxin inhibitor is an oxidizing agent, e.g., an inhibitor of G6PD, such as, for example, pyridoxal 5'-phosphate, 1 fluoro-2,4 dinitrobenzene, dehydroepiandrosterone (DHEA) or epiandrosterone (EA) ; cystine or cysteine.
  • an inhibitor of G6PD such as, for example, pyridoxal 5'-phosphate, 1 fluoro-2,4 dinitrobenzene, dehydroepiandrosterone (DHEA) or epiandrosterone (EA) ; cystine or cysteine.
  • DHEA dehydroepiandrosterone
  • EA epiandrosterone
  • cystine or cysteine cysteine.
  • Typical effective inhibitor concentrations of DHEA are between abour 0.05 mM and about 5 mM, or between about 0.1 mM and about 2.5 mM.
  • the thioredoxin inhibitor is an inhibitor of hexokinase activity, including, without limitation, chelators of metal ions, such as, for example, ethylenediamine tetraacetic acid (EDTA).
  • EDTA is typically added and effective at a concentration between about 5 mM and about 60 mM, or about 10 mM and about 50 mM, or about 20 mM and about 40 mM.
  • the inhibitor of hexokinase activity is selected from the group consisting of sorbose-1-phosphate, polyphosphates, 6-deoxy-6-fluoroglucose, 2-C-hydroxy-methyl glucose, xylose, and lyxose.
  • inhibitors include cystine, cysteine, and oxidized glutathione which are typically added at a concentration at least about 40-times of the concentration of the polypeptide in question in the pre-harvest or harvested culture fluid.
  • the thioredoxin inhibitor is an s iRNA, an antisense nucleotide, or an antibody specifically binding to a thioredoxin reductase.
  • the thioredoxin inhibitor is a measure indirectly resulting in the inhibition of thioredoxin activity.
  • This embodiment includes, for example, air sparging the harvested culture fluid of the recombinant host cell, and/or lowering the pH of the harvested culture fluid of the recombinant host cell.
  • indirect means for inhibiting thioredoxin activity such as air sparging and/or lowering of the pH, can be combined with the use of direct thioredoxin inhibitors, such as those listed above.
  • the polypeptide may, for example, be an antibody, or a biologically functional fragment of an antibody.
  • Representative antibody fragments include Fab, Fab', F(ab') 2 , scFv, (scFv) 2 , dAb, complementarity determining region (CDR) fragments, linear antibodies, single-chain antibody molecules, minibodies, diabodies, and multispecific antibodies formed from antibody fragments.
  • Therapeutic antibodies include, without limitation, anti-HER2 antibodies anti-CD20 antibodies; anti-lL-8 antibodies; anti-VEGF antibodies; anti-CD40 antibodies, anti-CD11a antibodies; anti-CD18 antibodies; anti-IgE antibodies; anti-Apo-2 receptor antibodies; anti-Tissue Factor (TF) antibodies; anti-human ⁇ 4 ⁇ 7 integrin antibodies; anti-EGFR antibodies; anti-CD3 antibodies; anti-CD25 antibodies; anti-CD4 antibodies; anti-CD52 antibodies; anti-Fc receptor antibodies; anti-carcinoembryonic antigen (CEA) antibodies; antibodies directed against breast epithelial cells; antibodies that bind to colon carcinoma cells; anti-CD38 antibodies; anti-CD33 antibodies; anti-CD22 antibodies; anti-EpCAM antibodies; anti-GpIIb/IIIa antibodies; anti-RSV antibodies; anti-CMV antibodies; anti-HIV antibodies; anti-hepatitis antibodies; anti-CA 125 antibodies; anti- ⁇ v ⁇ 3 antibodies; anti-human renal cell carcinoma antibodies; anti-human 17-1
  • the therapeutic antibody is an antibody binding to a HER receptor, VEGF, IgE, CD20, CD11a, CD40, or DR5.
  • the HER receptor is HER1 and/or HER2, preferably HER2.
  • the HER2 antibody may, for example, comprise a heavy and/or light chain variable domain sequence selected from the group consisting of SEQ ID NO: 16, 17, 18, and 19.
  • the therapeutic antibody is an antibody that binds to CD20.
  • the anti-CD20 antibody may, for example, comprise a heavy and/or light chain variable domain sequence selected from the group consisting of SEQ ID NOS: 1 through 15.
  • the therapeutic antibody is an antibody that binds to VEGF.
  • the anti-VEGF antibody may, for example, comprise a heavy and/or light chain variable domain sequence selected from the group consisting of SEQ ID NOS: 20 through 25.
  • the therapeutic antibody is an antibody that binds CD11a.
  • the anti-CD11a antibody may, for example, comprise a heavy and/or light chain variable domain sequence selected from the group consisting of SEQ ID NOS: 26 through 29.
  • the therapeutic antibody binds to a DR5 receptor.
  • the anti-DR5 antibody may, for example, be selected from the group consisting of Apomabs 1.1, 2.1, 3.1, 4.1, 5.1, 5.2, 5.3 , 6.1, 6.2, 6.3, 7.1, 7.2, 7.3,8.1, 8.3, 9.1, 1.2, 2.2, 3.2, 4.2, 5.2, 6.2, 7.2, 8.2, 9.2, 1.3, 2.2, 3.3, 4.3, 5.3, 6.3, 7.3, 8.3, 9.3, and 25.3, and preferably is Apomab 8.3 or Apomab 7.3, and most preferably Apomab 7.3.
  • the polypeptide expressed in the recombinant host cell is a therapeutic polypeptide.
  • the therapeutic polypeptide can be selected from the group consisting of a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; en
  • the recombinant host cell can be an eukaryotic host cell.
  • a mammalian host cell including, for example, Chinese Hamster Ovary (CHO) cells.
  • the recombinant host cell can also be a prokaryotic host cell, such as a bacterial cell, including, without limitation, E. coli cells.
  • the term “reduction” is used to refer to the reduction of one or more disulfide bonds of the protein or antibody.
  • the terms “ocrelizumab reduction” is used interchangeably with the term “ocrelizumab disulfide bond reduction”
  • the term “antibody (Ab) reduction” is used interchangeably with the term “antibody (Ab) disulfide bond reuction.”
  • reduction or “disulfide bond reduction” are used in the broadest sense, and include complete and partial reduction and reduction of some or all of the disulfide bonds, interchain or intrachain, present in a protein such as an antibody.
  • protein is meant a sequence of amino acids for which the chain length is sufficient to produce the higher levels of tertiary and/or quaternary structure. This is to distinguish from “peptides” or other small molecular weight drugs that do not have such structure.
  • the protein herein will have a molecular weight of at least about 15-20 kD, preferably at least about 20 kD.
  • proteins encompassed within the definition herein include all mammalian proteins, in particular, therapeutic and diagnostic proteins, such as therapeutic and diagnostic antibodies, and, in general proteins that contain one or more disulfide bonds, including multi-chain polypeptides comprising one or more inter- and/or intrachain disulfide bonds.
  • therapeutic protein or “therapeutic polypeptide” refers to a protein that is used in the treatment of disease, regardless of its indication or mechanism of action. In order for therapeutic proteins to be useful in the clinic it must be manufactured in large quantities.
  • Manufacturing scale production of therapeutic proteins, or other proteins, utilize cell cultures ranging from about 400L to about 80,000 L, depending on the protein being produced and the need. Typically such manufacturing scale production utilizes cell culture sizes from about 400 L to about 25,000 L. Within this range, specific cell culture sizes such as 4,000 L, about 6,000 L, about 8,000, about 10,000, about 12,000 L, about 14,000 L, or about 16,000 L are utilized.
  • therapeutic antibody refers to an antibody that is used in the treatment of disease.
  • a therapeutic antibody may have various mechanisms of action.
  • a therapeutic antibody may bind and neutralize the normal function of a target associated with an antigen.
  • a monoclonal antibody that blocks the activity of the of protein needed for the survival of a cancer cell causes the cell's death.
  • Another therapeutic monoclonal antibody may bind and activate the normal function of a target associated with an antigen.
  • a monoclonal antibody can bind to a protein on a cell and trigger an apoptosis signal.
  • Yet another monoclonal antibody may bind to a target antigen expressed only on diseased tissue; conjugation of a toxic payload (effective agent), such as a chemotherapeutic or radioactive agent, to the monoclonal antibody can create an agent for specific delivery of the toxic payload to the diseased tissue, reducing harm to healthy tissue.
  • a toxic payload such as a chemotherapeutic or radioactive agent
  • a "biologically functional fragment" of a therapeutic antibody will exhibit at least one if not some or all of the biological functions attributed to the intact antibody, the function comprising at least specific binding to the target antigen.
  • diagnosis protein refers to a protein that is used in the diagnosis of a disease.
  • diagnostic antibody refers to an antibody that is used as a diagnostic reagent for a disease.
  • the diagnostic antibody may bind to a target antigen that is specifically associated with, or shows increased expression in, a particular disease.
  • the diagnostic antibody may be used, for example, to detect a target in a biological sample from a patient, or in diagnostic imaging of disease sites, such as tumors, in a patient.
  • a "biologically functional fragment" of a diagnostic antibody will exhibit at least one if not some or all of the biological functions attributed to the intact antibody, the function comprising at least specific binding to the target antigen.
  • “Purified” means that a molecule is present in a sample at a concentration of at least 80-90% by weight of the sample in which it is contained.
  • the protein, including antibodies, which is purified is preferably essentially pure and desirably essentially homogeneous (i.e. free from contaminating proteins etc.).
  • An "essentially pure” protein means a protein composition comprising at least about 90% by weight of the protein, based on total weight of the composition, preferably at least about 95% by weight.
  • An "essentially homogeneous" protein means a protein composition comprising at least about 99% by weight of protein, based on total weight of the composition.
  • the protein is an antibody.
  • Antibodies (Abs) and “immunoglobulins” (lgs) are glycoproteins having the same structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which generally lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.
  • antibody is used in the broadest sense and specifically covers monoclonal antibodies (including full length antibodies which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies, and single-chain molecules such as scFv molecules, as well as antibody fragments ( e.g ., Fab, F(ab') 2 , and Fv).
  • a monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the modifier “monoclonal” indicates the character of the antibody as not being a mixture of discrete antibodies.
  • such a monoclonal antibody typically includes an antibody comprising a polypeptide sequence that binds a target, wherein the target-binding polypeptide sequence was obtained by a process that includes the selection of a single target binding polypeptide sequence from a plurality of polypeptide sequences.
  • the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, or recombinant DNA clones.
  • a selected target binding sequence can be further altered, for example, to improve affinity for the target, to humanize the target binding sequence, to improve its production in cell culture, to reduce its immunogenicity in vivo, to create a multispecific antibody, etc., and that an antibody comprising the altered target binding sequence is also a monoclonal antibody of this invention.
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
  • monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including, for example, the hybridoma method ( e.g. , Kohler et al., Nature, 256: 495 (1975 ); Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed.
  • the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity ( U.S. Patent No. 4,816,567 ; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984 )).
  • Humanized forms of non-human (e.g ., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
  • a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity.
  • donor antibody such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity.
  • framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody.
  • a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all the FRs are those of a human immunoglobulin sequence.
  • the humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • the humanized antibody includes a Primatized TM antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest.
  • a "human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies as disclosed herein. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
  • affinity matured antibody is one with one or more alterations in one or more CDRs/HVRs thereof which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration(s).
  • Preferred affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen.
  • Affinity matured antibodies are produced by procedures known in the art. Marks et al., Bio/Technology 10:779-783 (1992 ) describes affinity maturation by V H and V L domain shuffling. Random mutagenesis of CDR/HVR and/or framework residues is described by: Barbas et al., Proc Nat. Acad. Sci.
  • variable region or “variable domain” of an antibody refers to the amino-terminal domains of the heavy or light chain of the antibody.
  • the variable domain of the heavy chain may be referred to as "V H .”
  • the variable domain of the light chain may be referred to as "V L .” These domains are generally the most variable parts of an antibody and contain the antigen-binding sites.
  • variable refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed throughout the variable domains of antibodies. It is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions (HVRs) both in the light-chain and the heavy-chain variable domains. The more highly conserved portions of variable domains are called the framework regions (FR).
  • CDRs complementarity-determining regions
  • HVRs hypervariable regions
  • FR framework regions
  • the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure.
  • the CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen-binding site of antibodies (see Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, MD (1991 )).
  • the constant domains are not involved directly in the binding of an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.
  • the "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequences of their constant domains.
  • antibodies can be assigned to different classes.
  • immunoglobulins There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 .
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, d, e, g, and m, respectively.
  • An antibody may be part of a larger fusion molecule, formed by covalent or non-covalent association of the antibody with one or more other proteins or peptides.
  • full length antibody “intact antibody” and “whole antibody” are used herein interchangeably to refer to an antibody in its substantially intact form, not antibody fragments as defined below.
  • Antibody fragments comprise only a portion of an intact antibody, wherein the portion retains at least one, and as many as most or all, of the functions normally associated with that portion when present in an intact antibody.
  • an antibody fragment comprises an antigen binding site of the intact antibody and thus retains the ability to bind antigen.
  • an antibody fragment for example one that comprises the Fc region, retains at least one of the biological functions normally associated with the Fc region when present in an intact antibody, such as FcRn binding, antibody half life modulation, ADCC function and complement binding.
  • an antibody fragment is a monovalent antibody that has an in vivo half life substantially similar to an intact antibody.
  • such an antibody fragment may comprise an antigen binding arm linked to an Fc sequence capable of conferring in vivo stability to the fragment.
  • Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site, and a residual "Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
  • the Fab fragment contains the heavy- and light-chain variable domains and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain.
  • Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region.
  • Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
  • F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
  • Fv is the minimum antibody fragment which contains a complete antigen-binding site.
  • a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association.
  • scFv single-chain Fv
  • one heavy- and one light-chain variable domain can be covalently linked by a flexible peptide linker such that the light and heavy chains can associate in a "dimeric" structure analogous to that in a two-chain Fv species. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V H -V L dimer.
  • the six CDRs confer antigen-binding specificity to the antibody.
  • ⁇ "Single-chain Fv" or "scFv” antibody fragments comprise the V H and V L domains of an antibody, wherein these domains are present in a single polypeptide chain.
  • the scFv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the scFv to form the desired structure for antigen binding.
  • diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) in the same polypeptide chain (V H -V L ).
  • V H heavy-chain variable domain
  • V L light-chain variable domain
  • Diabodies may be bivalent or bispecific. Diabodies are described more fully in, for example, EP 404,097 ; WO93/1161 ; Hudson et al., (2003) Nat. Med. 9:129-134 ; and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993 ). Triabodies and tetrabodies are also described in Hudson et al., (2003) Nat. Med. 9:129-134 .
  • the antibody may bind to any protein, including, witout limitation, a member of the HER receptor family, such as HER1 (EGFR), HER2, HER3 and HER4; CD proteins such as CD3, CD4, CD8, CD19, CD20, CD21, CD22, and CD34; cell adhesion molecules such as LFA-1, Mol, p150,95, VLA-4, ICAM-1, VCAM and av/p3 integrin including either ⁇ or ⁇ or subunits thereof (e.g.
  • anti-CD11a, anti-CD18 or anti-CD11b antibodies growth factors such as vascular endothelial growth factor (VEGF); IgE; blood group antigens; flk2/flt3 receptor; obesity (OB) receptor; and protein C.
  • VEGF vascular endothelial growth factor
  • IgE IgE
  • blood group antigens flk2/flt3 receptor
  • OB obesity receptor
  • protein C protein C
  • exemplary proteins include growth hormone (GH), including human growth hormone (hGH) and bovine growth hormone (bGH); growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; ⁇ -1 - antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor , tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or tissue-type plasminogen activator (t-PA); bombazine; thrombin; tumor necrosis factor- ⁇ and - ⁇ ; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1- ⁇ ); serum albumin such as human serum albumin (HSA); mul
  • a "biologically functional fragment" of an antibody comprises only a portion of an intact antibody, wherein the portion retains at least one, and as many as most or all, of the functions normally associated with that portion when present in an intact antibody.
  • a biologically functional fragment of an antibody comprises an antigen binding site of the intact antibody and thus retains the ability to bind antigen.
  • a biologically functional fragment of an antibody for example one that comprises the Fc region, retains at least one of the biological functions normally associated with the Fc region when present in an intact antibody, such as FcRn binding, antibody half life modulation, ADCC function and complement binding.
  • a biologically functional fragment of an antibody is a monovalent antibody that has an in vivo half life substantially similar to an intact antibody.
  • such a biologically functional fragment of an antibody may comprise an antigen binding arm linked to an Fc sequence capable of conferring in vivo stability to the fragment.
  • thioredoxin inhibitor and “Trx inhibitor” are used interchangeably, and include all agents and measures effective in inhibiting thioredoxin activity.
  • thioredoxin (Trx) inhibitors include all agents and measures blocking any component of the Trx, G6PD and/or hexokinase enzyme systems.
  • inhibitor includes complete elimination (blocking) and reduction of thioredoxin activity, and, consequently, complete or partial elimination of disulfide bond reduction in a protein, such as an antibody.
  • an “isolated” antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with research, diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • an antibody is purified (1) to greater than 95% by weight of antibody as determined by, for example, the Lowry method, and in some embodiments, to greater than 99% by weight; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of, for example, a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using, for example, Coomassie blue or silver stain.
  • Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • Protein A and “ProA” are used interchangeably herein and encompasses Protein A recovered from a native source thereof, Protein A produced synthetically ( e.g . by peptide synthesis or by recombinant techniques), and variants thereof which retain the ability to bind proteins which have a C H 2/C H 3 region, such as an Fc region.
  • Protein A can be purchased commercially from Repligen, GE Healthcare and Fermatech. Protein A is generally immobilized on a solid phase support material.
  • the term “ProA” also refers to an affinity chromatography resin or column containing chromatographic solid support matrix to which is covalently attached Protein A.
  • chromatography refers to the process by which a solute of interest in a mixture is separated from other solutes in a mixture as a result of differences in rates at which the individual solutes of the mixture migrate through a stationary medium under the influence of a moving phase, or in bind and elute processes.
  • affinity chromatography and "protein affinity chromatography” are used interchangeably herein and refer to a protein separation technique in which a protein of interest or antibody of interest is reversibly and specifically bound to a biospecific ligand.
  • the biospecific ligand is covalently attached to a chromatographic solid phase material and is accessible to the protein of interest in solution as the solution contacts the chromatographic solid phase material.
  • the protein of interest e.g. , antibody, enzyme, or receptor protein
  • Binding of the protein of interest to the immobilized ligand allows contaminating proteins or protein impurities to be passed through the chromatographic medium while the protein of interest remains specifically bound to the immobilized ligand on the solid phase material.
  • the specifically bound protein of interest is then removed in active form from the immobilized ligand with low pH, high pH. high salt, competing ligand, and the like, and passed through the chromatographic column with the elution buffer, free of the contaminating proteins or protein impurities that were earlier allowed to pass through the column.
  • Any component can be used as a ligand for purifying its respective specific binding protein, e . g . antibody.
  • non-affinity chromatography and “non-affinity purification” refer to a purification process in which affinity chromatography is not utilized.
  • Non-affinity chromatography includes chromatographic techniques that rely on non-specific interactions between a molecule of interest (such as a protein, e . g . antibody) and a solid phase matrix.
  • a “cation exchange resin” refers to a solid phase which is negatively charged, and which thus has free cations for exchange with cations in an aqueous solution passed over or through the solid phase.
  • a negatively charged ligand attached to the solid phase to form the cation exchange resin may, e.g., be a carboxylate or sulfonate.
  • Commercially available cation exchange resins include carboxy-methyl-cellulose, sulphopropyl (SP) immobilized on agarose (e.g. SP-SEPHAROSE FAST FLOW TM or SP-SEPHAROSE HIGH PERFORMANCE TM , from GE Healthcare) and sulphonyl immobilized on agarose (e.g .
  • a "mixed mode ion exchange resin” refers to a solid phase which is covalently modified with cationic, anionic, and hydrophobic moieties.
  • a commercially available mixed mode ion exchange resin is BAKERBOND ABX TM (J.T. Baker, Phillipsburg, NJ) containing weak cation exchange groups, a low concentration of anion exchange groups, and hydrophobic ligands attached to a silica gel solid phase support matrix.
  • anion exchange resin is used herein to refer to a solid phase which is positively charged, e.g . having one or more positively charged ligands, such as quaternary amino groups, attached thereto.
  • commercially available anion exchange resins include DEAE cellulose, QAE SEPHADEX TM and FAST Q SEPHAROSE TM (GE Healthcare).
  • a “buffer” is a solution that resists changes in pH by the action of its acid-base conjugate components.
  • Various buffers which can be employed depending, for example, on the desired pH of the buffer are described in Buffers. A Guide for the Preparation and Use of Buffers in Biological Systems, Gueffroy, D., ed. Calbiochem Corporation (1975 ).
  • the buffer has a pH in the range from about 2 to about 9, alternatively from about 3 to about 8, alternatively from about 4 to about 7 alternatively from about 5 to about 7.
  • Non-limiting examples of buffers that will control the pH in this range include MES, MOPS, MOPSO, Tris, HEPES, phosphate, acetate, citrate, succinate, and ammonium buffers, as well as combinations of these.
  • the "loading buffer” is that which is used to load the composition comprising the polypeptide molecule of interest and one or more impurities onto the ion exchange resin.
  • the loading buffer has a conductivity and/or pH such that the polypeptide molecule of interest (and generally one or more impurities) is/are bound to the ion exchange resin or such that the protein of interest flows through the column while the impurities bind to the resin.
  • the "intermediate buffer” is used to elute one or more impurities from the ion exchange resin, prior to eluting the polypeptide molecule of interest.
  • the conductivity and/or pH of the intermediate buffer is/are such that one or more impurity is eluted from the ion exchange resin, but not significant amounts of the polypeptide of interest.
  • wash buffer when used herein refers to a buffer used to wash or re-equilibrate the ion exchange resin, prior to eluting the polypeptide molecule of interest. Conveniently, the wash buffer and loading buffer may be the same, but this is not required.
  • the "elution buffer” is used to elute the polypeptide of interest from the solid phase.
  • the conductivity and/or pH of the elution buffer is/are such that the polypeptide of interest is eluted from the ion exchange resin.
  • a “regeneration buffer” may be used to regenerate the ion exchange resin such that it can be re-used.
  • the regeneration buffer has a conductivity and/or pH as required to remove substantially all impurities and the polypeptide of interest from the ion exchange resin.
  • substantially similar denotes a sufficiently high degree of similarity between two numeric values (for example, one associated with an antibody of the invention and the other associated with a reference/comparator antibody), such that one of skill in the art would consider the difference between the two values to be of little or no biological and/or statistical significance within the context of the biological characteristic measured by said values (e.g ., Kd values).
  • the difference between said two values is, for example, less than about 50%, less than about 40%, less than about 30%, less than about 20%, and/or less than about 10% as a function of the reference/comparator value.
  • vector is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA into which additional DNA segments may be ligated.
  • phage vector refers to a viral vector, wherein additional DNA segments may be ligated into the viral genome.
  • viral vector is capable of autonomous replication in a host cell into which they are introduced (e.g ., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • vectors e.g ., non-episomal mammalian vectors
  • vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors are capable of directing the expression of genes to which they are operatively linked.
  • Such vectors are referred to herein as "recombinant expression vectors," or simply, "expression vectors.”
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector may be used interchangeably as the plasmid is the most commonly used form of vector.
  • Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
  • % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
  • the ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
  • % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows:
  • Percent (%) nucleic acid sequence identity is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in a reference Factor D-encoding sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Sequence identity is then calculated relative to the longer sequence, i.e. even if a shorter sequence shows 100% sequence identity wit a portion of a longer sequence, the overall sequence identity will be less than 100%.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. “Treatment” herein encompasses alleviation of the disease and of the signs and symptoms of the particular disease.
  • a “disorder” is any condition that would benefit from treatment with the protein. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
  • disorders to be treated herein include carcinomas and allergies.
  • mammal for purposes of treatment refers to any animal classified as a mammal, including humans, non-human higher primates, other vertebrates, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc.
  • the mammal is human.
  • Interfering RNA or "small interfering RNA (siRNA)” is a double stranded RNA molecule less than about 30 nucleotides in length that reduces expression of a target gene. Interfering RNAs may be identified and synthesized using known methods ( Shi Y., Trends in Genetics 19(1):9-12 (2003 ), WO/2003056012 and WO2003064621 ), and siRNA libraries are commercially available, for example from Dharmacon, Colorado. Frequently, siRNAs can be successfully designed to target the 5' end of a gene.
  • the present invention concerns methods for the prevention of the reduction of disulfide bonds of proteins during recombinant production.
  • the invention concerns methods for preventing the reduction of disulfide bonds of recombinant proteins during processing following fermentation.
  • the methods of the invention are particulary valuable for large scale production of disulfide bond containing proteins, such as at a manufacturing scale.
  • the methods of the invention are useful for large scale protein production at a scale of greater than 5,000 L.
  • disulfide bond reduction occurs during processing of the Harvested Cell Culture Fluid (HCCF) produced during manufacturing of recombinant proteins that contain disulfide bonds.
  • HCCF Harvested Cell Culture Fluid
  • this reduction is observed after cell lysis, especially mechanical cell lysis during harvest operations, when it reaches a certain threshold, such as, for example, from about 30% to about 70%, or from about 40% to about 60%, or from about 50% to about 60% total cell lysis.
  • This threshold will vary, depending on the nature of the protein (e.g. antibody) produced, the recombinant host, the production system, production parameters used, and the like, and can be readily determined experimentally.
  • Such reduction might result from a variety of factors and conditions during the manufacturing process, and might be caused by a variety of reducing agents.
  • the present invention is based, at least in part, on the recognition that the root cause of this reduction is an active thioredoxin (Trx) or thioredoxin-like system in the HCCF.
  • Trx The Trx enzyme system, composed of Trx, thioredoxin reductase (TrxR) and NADPH, is a hydrogen donor system for reduction of disulfide bonds in proteins.
  • Trx is a small monomeric protein with a CXXC active site motif that catalyzes many redox reactions through thiol-disulfide exchange.
  • the oxidized Trx can be reduced by NADPH via TrxR.
  • the reduced Trx is then able to catalyze the reduction of disulfides in proteins.
  • the NADPH required for thioredoxin system is provided via reactions in pentose phosphate pathway and glycolysis.
  • NADPH which is required for activity of the Trx system is provided by glucose-6-phosphate dehyrogenase (G6PD) activity, which generates NADPH from glucose and ATP by hexokinase (see Figure 4 ).
  • G6PD glucose-6-phosphate dehyrogenase
  • These cellular enzymes (Trx system, G6PD, and hexokinase) along with their substrates are released into the CCF upon cell lysis, allowing reduction to occur. Accordingly, disulfide reduction can be prevented by inhibitors of the Trx enzyme system or upstream enzyme systems providing components for an active Trx system, such as G6PD and hexokinase activity.
  • LDH Lactate Dehydrogenase
  • disulfide bond reduction can be prevented by blocking any component of the Trx, G6PD and hexokinase enzyme systems.
  • Inhibitors of these enzyme systems are collectively referred to herein as “thioredoxin inhibitors," or "Trx inhibitors.”
  • the Trx inhibitors are typically added to the cell culture fluid (CCF), which contains the recombinant host cells and the culture media, and/or to the harvested cell culture fluid (HCCF), which is obtained after harvesting by centrifugation, filtration, or similar separation methods.
  • the HCCF lacks intact host cells but typically contains host cell proteins and other contaminants, including DNA, which are removed in subsequent purification steps.
  • the Trx inhibitors may be added before harvest and/or during harvest, preferably before harvest.
  • non-specific methods can also be used to prevent the reduction of disulfide bond reduction following fermentation during the recombinant production of recombinant proteins, such as air sparging or pH adjustment.
  • Certain reduction inhibition methods contemplated herein are listed in the following Table 1.
  • Table 1 Reduction Inhibition Methods Method 1 Purpose Addition of EDTA, EGTA, or citrate To inhibit hexokinase Addition of sorbose-1-phosphate, polyphosphates, 6-deoxy-6-fluoroglucose, 2-C-hydroxy-methylglucose, xylose, or lyxose To inhibit hexokinase Addition of epiandrosterone or dehydroepiandrosterone (DHEA) To inhibit G6PD Addition of pyridoxal 5'-phosphate or 1-fluoro-2,4-dinitrobenzene To inhibit G6PD Addition of metal ions such as Cu 2+ , Zn 2+ Hg 2+ , Co 2+ , or Mn 2+ To inhibit Trx system Addition of alkyl-2-imidazolyl disulfides and related compounds (e.g.
  • Trx inhibitors for use in the methods of the present invention include, without limitation, (1) direct inhibitors of Trx, such as alkyl-2-imidazolyl disulfides and related compounds (e.g. , 1 methylpropyl-2-imidazolyl disulfide) (Kirkpatrick et al. , 1998 and 1999, supra ) and naphthoquinone spiroketal derivatives ( e.g. , palmarumycin CP 1 ) (Wipf et al.
  • direct inhibitors of Trx such as alkyl-2-imidazolyl disulfides and related compounds (e.g. , 1 methylpropyl-2-imidazolyl disulfide) (Kirkpatrick et al. , 1998 and 1999, supra ) and naphthoquinone spiroketal derivatives (e.g. , palmarumycin CP 1 ) (Wipf et al.
  • direct inhibitors of Trx such
  • TrxR specific inhibitors of TrxR, including gold complexes, such as aurothioglucose (ATG) and aurothiomalate (ATM) (see, e.g ., the review by Gromer et al.
  • ATG aurothioglucose
  • ATM aurothiomalate
  • TrxR irreversible inhibitors of TrxR
  • metal ions such as Hg 2+ , Cu 2+ , Zn 2+ , Co 2+ , and Mn 2+ , which can form readily complexes with thiols and selenols, and thus can be used in embodiments of the instant invention as inhibitors of TrxR or Trx
  • inhibitors of G6PD such as, for example, pyridoxal 5'-phosphate and 1 fluoro-2,4 dinitrobenzene (Milhausen and Levy 1975, supra ), certain steroids, such as dehydroepiandrosterone (DHEA) and epiandrosterone (EA) (Gordon et al., 1995, supra ); and (4) inhibitors of hexokinase activity (and thereby production of G6P for the G6PD), including chelators of metal ions, e .
  • DHEA dehydroepiandrosterone
  • EA epiandrosterone
  • Trx inhibitors such as EDTA, and compounds that react with SH groups, sorbose-1-phosphate, polyphosphates, 6-deoxy-6-fluoroglucose, 2-C-hydroxy-methylglucose, xylose and lyxose (Sols et al. , 1958, supra ; McDonald, 1955, supra ); further hexokinase inhibitors are disclosed in U.S. Patent No. 5,854,067 entitled "Hexokinase Inhibitors.” It will be understood that these inhibitors are listed for illustration only. Other Trx inhibitors exists and can be used, alone or in various combinations, in the methods of the present invention.
  • Trx inhibitors for use in the methods of the present invention also include reagents whereby the reduction of recombinantly produced antibodies or proteins may be reduced or prevented by decreasing the levels of enzymes of the Trx system, the pentose phosphate pathway or hexokinase at various points during the production campaign. In some embodiments, this reduction of enzyme levels may be accomplished by the use of targeted siRNAs, antisense nucleotides, or antibodies. To design targeted siRNAs or antisense nucleotides to the genes as found in CHO cells, these gene sequences are available from public databases to select sequences for targeting enzymes in different organisms. See Example 9 below for examples of the genes of the E. coli and mouse Trx system.
  • a recombinant protein in addition to using inhibitors discussed above, it is also possible in certain embodiments of the instant invention to prevent the reduction of a recombinant protein to be purifed by sparging the HCCF with air to maintain an oxidizing redox potential in the HCCF.
  • This is a non-directed measure that can deplete glucose, G6P and NADPH by continuously oxidizing the reduced forms of Trx and TrxR.
  • Air sparging of the HCCF tank can be performed, for example, with an air flow of about 100 liters to about 200 liters, such as, for example, 150 liters per minutes.
  • Air sparging can be performed to reach an endpoint percentage of saturation; for example, air sparging can be continued until the HCCF is about 100% saturated with air, or it can be continued until the HCCR is about 30% saturated with air, or until it is between about 100% saturated to about 30% saturated with air.
  • the minimum amount of dissolved oxygen (dO 2 ) required for the desired inhibitory effect also depends on the antibody or other recombinant protein produced. Thus, for example, about 10% dO 2 (or about 10 sccm for continuous stream) will have the desired effect during the production of antibody 2H7 (Variant A), while Apomab might require a higher (about 30%) dO 2 .
  • another non-directed method usable to block the reduction of the recombinant protein is lowering the pH of the HCCF.
  • This embodiment takes advantage of particularly slow thiol-disulfide exchange at lower pH values (Whitesides et al. , 1977, supra ; pleasants et al. , 1989, supra ). Therefore, the activity of the Trx system is significantly lower at pH values below 6, and thus the reduction of the recombinant protein, such as ocrelizumab, can be inhibited.
  • the non-directed approaches can also be combined with each other and/or with the use of one or more Trx inhibitors.
  • Disulfide bond reduction can be inhibited ( i.e. , partially or fully blocked) by using one or more Trx inhibitors and/or applying non-directed approaches following completion of the cell culture process, preferably to CCF prior to harvest or in the HCCF immediately after harvest.
  • the optimal time and mode of application and effective amounts depend on the nature of the protein to be purified, the recombinant host cells, and the specific production method used. Determination of the optimal parameters is well within the skill of those of ordinary skill in the art.
  • cupric sulfate in the form of pentahydrate or the anhydrous form
  • CCF or HCCF in the concentration range of from about 5 ⁇ M to about 100 ⁇ M, such as from about 10 ⁇ M to about 80 ⁇ M, preferably from about 15 ⁇ M to about 50 ⁇ M.
  • copper e.g. about 0.04 ⁇ M CuSO 4 for the CHO cell cultures used in the Examples herein
  • this amount is in addition to the copper, if any, already present in the cell culture.
  • Any copper (II) salt can be used instead of CuSO 4 as long as solubility is not an issue.
  • copper acetate and copper chloride which are both soluble in water, can be used instead of CuSO 4 .
  • the minimum effective concentration may also depend on the antibody produced and the stage where the inhibitor is used. Thus, for example, when cupric sulfate is added pre-lysis, for antibody 2H7 (Variant A) the minimum effective concentration is about 30 ⁇ M, for Apomab is about 75 ⁇ M, and for antibody Variant C (see Table 2) is about 50 ⁇ M.
  • EDTA can be used in a wide concentration range, depending on the extent of cell lysis, the recombinant host cell used, and other parameters of the production process.
  • EDTA can be typically added in a concentration of between about 5 mM to about 60 mM, such as from about 10 mM to about 50 mM, or from about 20 mM to about 40 mM, depending on the extent of cell lysis.
  • concentrations of EDTA will suffice, while for a cell lysis of about 75% - 100%, the required EDTA concentration is higher, such as, for example, from about 20 mM to about 40 mM.
  • the minimum effective concentration may also depend on the antibody produced. Thus, for example, for antibody 2H7 (Variant A) the minimum effective EDTA concentration is about 10 mM.
  • DHEA as a Trx inhibitor is typically effective at a lower concentration, such as for example, in the concentration range from about 0.05 mM to about 5 mM. preferably from about 0.1 mM to about 2.5 mM.
  • Trx inhibitors such as aurothioglucose (ATG) and aurothiomalate (ATM) inhibit reduction of disulfide bonds in the ⁇ M concentration range.
  • ATG or ATM may be added in a concentration between about 0.1 mM to about 1 mM. While the minimum inhibitory concentration varies depending on the actual conditions, for ATG and ATM typically it is around 4 x TrxR concentration.
  • the mammalian host cell used in the manufacturing process is a chinese hamster ovary (CHO) cell ( Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980 )).
  • Other mammalian host cells include, without limitation, monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture), Graham et al., J. Gen Virol. 36:59 (1977 )); baby hamster kidney cells (BHK, ATCC CCL 10); mouse sertoli cells (TM4, Mather, Biol. Reprod.
  • monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells ( Mather et al., Annals N. Y. Acad. Sci.
  • MRC 5 cells MRC 5 cells; FS4 cells; a human hepatoma line (Hep G2); and myeloma or lymphoma cells ( e.g. Y0, J558L. P3 and NS0 cells) (see US Patent No. 5,807,715 ).
  • a preferred host cell for the production of the polypeptides herein is the CHO cell line DP12 (CHO K1 dhfr - ). This is one of the best known CHO cell lines, widely used in laboratory practice ( see , for example, EP 0,307,247, published March 15, 1989 ). In addition, other CHO-K1 (dhfr - ) cell lines are known and can be used in the methods of the present invention.
  • the mammalian host cells used to produce peptides, polypeptides and proteins can be cultured in a variety of media.
  • Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM, Sigma) are suitable for culturing the host cells.
  • any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as Gentamycin TM drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
  • the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • a protocol for the production, recovery and purification of recombinant antibodies in mammalian, such as CHO, cells may include the following steps: Cells may be cultured in a stirred tank bioreactor system and a fed batch culture, procedure is employed. In a preferred fed batch culture the mammalian host cells and culture medium are supplied to a culturing vessel initially and additional culture nutrients are fed, continuously or in discrete increments, to the culture during culturing, with or without periodic cell and/or product harvest before termination of culture.
  • the fed batch culture can include, for example, a semi-continuous fed batch culture, wherein periodically whole culture (including cells and medium) is removed and replaced by fresh medium.
  • Fed batch culture is distinguished from simple batch culture in which all components for cell culturing (including the cells and all culture nutrients) are supplied to the culturing vessel at the start of the culturing process.
  • Fed batch culture can be further distinguished from perfusion culturing insofar as the supernate is not removed from the culturing vessel during the process (in perfusion culturing, the cells are restrained in the culture by, e.g., filtration, encapsulation, anchoring to microcarriers etc. and the culture medium is continuously or intermittently introduced and removed from the culturing vessel).
  • the cells of the culture may be propagated according to any scheme or routine that may be suitable for the particular host cell and the particular production plan contemplated. Therefore, a single step or multiple step culture procedure may be employed.
  • a single step culture the host cells are inoculated into a culture environment and the processes are employed during a single production phase of the cell culture.
  • a multi-stage culture can be used.
  • cells may be cultivated in a number of steps or phases. For instance, cells may be grown in a first step or growth phase culture wherein cells, possibly removed from storage, are inoculated into a medium suitable for promoting growth and high viability. The cells may be maintained in the growth phase for a suitable period of time by the addition of fresh medium to the host cell culture.
  • fed batch or continuous cell culture conditions may be devised to enhance growth of the mammalian cells in the growth phase of the cell culture.
  • cells are grown under conditions and for a period of time that is maximized for growth.
  • Culture conditions such as temperature, pH, dissolved oxygen (dO 2 ) and the like, are those used with the particular host and will be apparent to the ordinarily skilled artisan.
  • the pH is adjusted to a level between about 6.5 and 7.5 using either an acid (e.g., CO 2 ) or a base (e.g., Na2CO 3 or NaOH).
  • a suitable temperature range for culturing mammalian cells such as CHO cells is between about 30°C to 38°C, and a suitable dO 2 is between 5-90% of air saturation.
  • the cells may be used to inoculate a production phase or step of the cell culture.
  • the production phase or step may be continuous with the inoculation or growth phase or step.
  • the cell culture environment during the production phase of the cell culture is typically controlled.
  • factors affecting cell specific productivity of the mammalian host cell may be manipulated such that the desired sialic acid content is achieved in the resulting glycoprotein.
  • the production phase of the cell culture process is preceded by a transition phase of the cell culture in which parameters for the production phase of the cell culture are engaged. Further details of this process are found in U.S. Patent No. 5,721,121 , and Chaderjian et al., Biotechnol. Prog. 21(2):550-3 (2005 ), the entire disclosures of which are expressly incorporated by reference herein.
  • the first step of a purification process involves lysis of the cell, which can be done by a variety of methods, including mechanical shear, osmotic shock, or enzymatic treatments. Such disruption releases the entire contents of the cell into the homogenate, and in addition produces subcellular fragments that are difficult to remove due to their small size. These are generally removed by differential centrifugation or by filtration. The same problem arises, although on a smaller scale, with directly secreted proteins due to the natural death of cells and release of intracellular host cell proteins and components in the course of the protein production run.
  • the desired protein is separated from impurities when the impurities specifically adhere to the column, and the protein of interest does not, that is, the protein of interest is present in the "flow-through.”
  • purification of recombinant proteins from the cell culture of mammalian host cells may include one or more affinity (e.g. protein A) and/or ion exchange chomarographic steps.
  • Ion exchange chromatography is a chromatographic technique that is commonly used for the purification of proteins.
  • ion exchange chromatography charged patches on the surface of the solute are attracted by opposite charges attached to a chromatography matrix, provided the ionic strength of the surrounding buffer is low. Elution is generally achieved by increasing the ionic strength (i.e. conductivity) of the buffer to compete with the solute for the charged sites of the ion exchange matrix.
  • Changing the pH and thereby altering the charge of the solute is another way to achieve elution of the solute.
  • the change in conductivity or pH may be gradual (gradient elution) or stepwise (step elution). In the past, these changes have been progressive; i.e., the pH or conductivity is increased or decreased in a single direction.
  • yeast host cells such as common baker's yeast or Saccharomyces cerevisiae
  • suitable vectors include episomally-replicating vectors based on the 2-micron plasmid, integration vectors, and yeast artificial chromosome (YAC) vectors.
  • yeast suitable for recombinant production of heterologous proteins include Schizosaccharomyces pombe ( Beach and Nurse, Nature, 290: 140 (1981 ); EP 139,383 published 2 May 1985 ); Kluyveromyces hosts ( U.S. Pat. No.
  • filamentous fungi such as, e.g ., Neurospora , Penicillium , Tolypocladium ( WO 91/00357 published 10 Jan. 1991 ), and Aspergillus hosts such as A. nidulans ( Ballance et al., Biochem. Biophys. Res. Commun., 112: 284 289 (1983 ); Tilburn et al., Gene, 26: 205 221 (1983 ); Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470 1474 (1984 )) and A. niger ( Kelly and Hynes, EMBO J., 4: 475 479 (1985 )).
  • Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Hansenula , Candida , Kloeckera , Pichia , Saccharomyces , Torulopsis , and Rhodotorula .
  • yeast capable of growth on methanol selected from the genera consisting of Hansenula , Candida , Kloeckera , Pichia , Saccharomyces , Torulopsis , and Rhodotorula .
  • a list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotrophs, 269 (1982 ). Expression systems for the listed and other yeasts are well known in the art and/or are commercially available.
  • suitable vectors include baculoviral vectors.
  • suitable expression vectors include vectors derived from the Ti plasmid of
  • Agrobacterium tumefaciens Agrobacterium tumefaciens .
  • Prokaryotic host cells suitable for expressing antibodies and other proteins to be protected by means of the instant invention include Archaebacteria and Eubacteria , such as Gram-negative or Gram-positive organisms.
  • useful bacteria include Escherichia (e.g. , E. coli ), Bacilli ( e.g. , B. subtilis ), Enterobacteria , Pseudomonas species ( e.g. , P.
  • E. coli strains include strain W3110 ( Bachmann, Cellular and Molecular Biology, vol. 2 (Washington, D.C.: American Society for Microbiology, 1987), pp. 1190-1219 ; ATCC Deposit No.
  • strain 33D3 having genotype W3110 ⁇ fhuA ( ⁇ tonA) ptr3 lac Iq lacL8 ⁇ ompT ⁇ (nmpc-fepE) degP41 kanR ( U.S. Pat. No. 5,639,635 ).
  • Other strains and derivatives thereof such as E. coli 294 (ATCC 31,446), E. coli B, E. coli l 1776 (ATCC 31,537) and E. coli RV308(ATCC 31,608) are also suitable. These examples are illustrative rather than limiting.
  • Cell lysis is typically accomplished using mechanical disruption techniques such as homogenization or head milling. While the protein of interest is generally effectively liberated, such techniques have several disadvantages ( Engler, Protein Purification Process Engineering, Harrison eds., 37 55 (1994 )). Temperature increases, which often occur during processing, may result in inactivation of the protein. Moreover, the resulting suspension contains a broad spectrum of contaminating proteins, nucleic acids, and polysaccharides. Nucleic acids and polysaccharides increase solution viscosity, potentially complicating subsequent processing by centrifugation, cross-flow filtration, or chromatography. Complex associations of these contaminants with the protein of interest can complicate the purification process and result in unacceptably low yields. Improved methods for purification of heterologous polypeptides from microbial fermentation broth or homogenate are described, for example, in U.S. Patent No. 7,169,908 , the entire disclosure of which is expressly incorporated herein by reference.
  • the methods of the present invention are used to prevent the reduction of inter- and/or intrachain disulfide bonds of antibodies, including therapeutic and diagnostic antibodies.
  • Antibodies within the scope of the present invention include, but are not limited to: anti-HER2 antibodies including Trastuzumab (HERCEPTIN ® ) ( Carter et al.. Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992 ), U.S. Patent No. 5,725,856 ); anti-CD20 antibodies such as chimeric anti-CD20 "C2B8" as in US Patent No. 5,736,137 (RITUXAN ® ), a chimeric or humanized variant of the 2H7 antibody as in US Patent No.
  • anti-VEGF antibodies including humanized and/or affinity matured anti-VEGF antibodies such as the humanized anti-VEGF antibody huA4.6.1 AVASTIN ® ( Kim et al., Growth Factors, 7:53-64 (1992 ), International Publication No.
  • anti-PSCA antibodies WO01/40309
  • anti-CD40 antibodies including S2C6 and humanized variants thereof ( WO00/75348 ); anti-CD11a ( US Patent No. 5,622,700 , WO 98/23761 , Steppe et al., Transplant Intl. 4:3-7 (1991 ), and Hourmant et al., Transplantation 58:377-380 (1994 )); anti-IgE ( Presta et al., J. Immunol. 151:2623-2632 (1993 ), and International Publication No. WO 95/19181 ); anti-CD18 ( US Patent No.
  • anti-CD25 or anti-tac antibodies such as CHI-621 (SIMULECT ® ) and (ZENAPAX ® ) ( See US Patent No. 5,693,762 issued December 2, 1997 ); anti-CD4 antibodies such as the cM-7412 antibody ( Choy et al., Arthritis Rheum 39(1):52-56 (1996 )); anti-CD52 antibodies such as CAMPATH-1H ( Riechmann et al., Nature 332:323-337 (1988 )); anti-Fc receptor antibodies such as the M22 antibody directed against Fc ⁇ RI as in Graziano et al., J. Immunol.
  • anti-carcinoembryonic antigen (CEA) antibodies such as hMN-14 ( Sharkey et al., Cancer Res. 55(23Suppl): 5935s-5945s (1995 ); antibodies directed against breast epithelial cells including huBrE-3, hu-Mc 3 and CHL6 ( Ceriani et al., Cancer Res. 55(23): 5852s-5856s (1995 ); and Richman et al., Cancer Res. 55(23 Supp): 5916s-5920s (1995 )); antibodies that bind to colon carcinoma cells such as C242 ( Litton et al., Eur J. Immunol.
  • anti-CD38 antibodies e.g. AT 13/5 ( Ellis et al., J. Immunol. 155(2):925-937 (1995 )); anti-CD33 antibodies such as Hu M195 ( Jurcic el al., Cancer Res 55(23 Suppl):5908s-5910s (1995 ) and CMA-676 or CDP771; anti-CD22 antibodies such as LL2 or LymphoCide ( Juweid et al., Cancer Res 55(23 Suppl):5899s-5907s (1995 )); anti-EpCAM antibodies such as 17-1A (PANOREX ® ); anti-GpIIb/IIIa antibodies such as abciximab or c7E3 Fab (REOPRO ® ); anti-RSV antibodies such as MEDI-493 (SYNAGIS ® ); anti-CMV antibodies such as PROTOVIR ® ; anti-HIV antibodies such as PRO542; anti-
  • the methods of the present invention are used for the production of the following antibodies and recombinant proteins.
  • Rituximab (RITUXAN ® ) is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen.
  • Rituximab is the antibody called "C2B8" in U.S. Pat. No. 5,736,137 issued Apr. 7, 1998 (Anderson et al. ) .
  • Rituximab is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, CD20-positive, B cell non-Hodgkin's lymphoma.
  • rituximab binds human complement and lyses lymphoid B cell lines through complement-dependent cytotoxicity (CDC) ( Reff et al., Blood 83(2):435-445 (1994 )). Additionally, it has significant activity in assays for antibody-dependent cellular cytotoxicity (ADCC). More recently, rituximab has been shown to have anti-proliferative effects in tritiated thymidine incorporation assays and to induce apoptosis directly, while other anti-CD19 and CD20 antibodies do not ( Maloney et al., Blood 88(10):637a (1996 )).
  • rituximab sensitizes drug-resistant human B cell lymphoma cell lines to the cytotoxic effects of doxorubicin, CDDP, VP-1 6, diphtheria toxin and ricin ( Demidem et al., Cancer Chemotherapy & Radiopharmaceuticals 12(3):177-186 (1997 )).
  • Patents and patent publications concerning CD20 antibodies include U.S. Pat. Nos. 5,776,456 , 5,736,137, 6,399,061, and 5,843,439 , as well as U.S. patent application Nos. US 2002/0197255A1 , US 2003/0021781A1 , US 2003/0082172 A1 , US 2003/0095963 A1 , US 2003/0147885 A1 (Anderson et al. ); U.S. Pat. No.
  • the invention provides pharmaceutical compositions comprising humanized 21-17 anti-CD20 antibodies.
  • the humanized 2H7 antibody is an antibody listed in Table 2.
  • Each of the antibody variants A, B and I of Table 2 comprises the light chain variable sequence (V L ): the heavy chain variable sequence (V H ):
  • Each of the antibody variants C, D, F and G of Table 2 comprises the light chain variable sequence (V L ): and the heavy chain variable sequence (V H ):
  • the antibody variant II of Table 2 comprises the light chain variable sequence (V L ) of SEQ ID NO:3 (above) and the heavy chain variable sequence (V H ):
  • Each of the antibody variants A, B and I of Table 2 comprises the full length light chain sequence:
  • Variant A of Table 2 comprises the full length heavy chain sequence:
  • Variant B of Table 2 comprises the full length heavy chain sequence:
  • Variant I of Table 2 comprises the full length heavy chain sequence:
  • Each of the antibody variants C. D, F, G and H of Table 2 comprises the full length light chain sequence:
  • Variant C of Table 2 comprises the full length heavy chain sequence:
  • Variant D of Table 2 comprises the full length heavy chain sequence:
  • Variant F of Table 2 comprises the full length heavy chain sequence:
  • Variant G of Table 2 comprises the full length heavy chain sequence:
  • Variant H of Table 2 comprises the full length heavy chain sequence:
  • the humanized 2H7 antibody of the invention further comprises amino acid alterations in the IgG Fc and exhibits increased binding affinity for human FcRn over an antibody having wild-type IgG Fc, by at least 60 fold, at least 70 fold, at least 80 fold, more preferably at least 100 fold, preferably at least 125 fold, even more preferably at least 150 fold to about 170 fold.
  • Humanized 2H7 antibody compositions of the present invention include compositions of any of the preceding humanized 2H7 antibodies having a Fc region, wherein about 80-100% (and preferably about 90-99%) of the antibody in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein.
  • Such compositions were demonstrated herein to exhibit a surprising improvement in binding to Fc(RIIIA(F158), which is not as effective as Fc(RIIIA (V158) in interacting with human IgG.
  • Fc(RIIIA (F158) is more common than Fc(RIIIA (V158) in normal, healthy African Americans and Caucasians. See Lehrnbecher et al., Blood 94:4220 (1999 ).
  • CHO Chinese Hamster Ovary Cells
  • YB2/0 and Lee13 can produce antibodies with 78 to 98% nonfucosylated species.
  • Shinkawa et al., J Bio. Chem. 278 (5), 3466-347 (2003 ) reported that antibodies produced in YB2/0 and Lec13 cells, which have less FUT8 activity, show significantly increased ADCC activity in vitro.
  • a bispecific humanized 2H7 antibody encompasses an antibody wherein one arm of the antibody has at least the antigen binding region of the H and/or L chain of a humanized 2H7 antibody of the invention, and the other arm has V region binding specificity for a second antigen.
  • the second antigen is selected from the group consisting of CD3, CD64, CD32A, CD16, NKG2D or other NK activating ligands.
  • a recombinant humanized version of the murine HER2 antibody 4D5 (huMAb4D5-8, rhuMAb HER2, trastuzumab or HERCEPTIN ® ; U.S. Patent No. 5,821,337 ) is clinically active in patients with HER2-overexpressing metastatic breast cancers that have received extensive prior anti-cancer therapy ( Baselga et al., J. Clin. Oncol. 14:737-744 (1996 )).
  • Trastuzumab received marketing approval from the Food and Drug Administration (FDA) September 25, 1998 for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein.
  • FDA Food and Drug Administration
  • the anti-HER2 antibody comprises the following V L and V H domain sequences:
  • the anti-HER2 antibody comprises the V L (SEQ ID NO:18) and V H (SEQ ID NO:19) domain sequences of trastuzumab as shown in Figure 21 and Figure 22 , respectively.
  • HER2 antibodies with various properties have been described in Tagliabue et al., Int. J. Cancer 47:933-937 (1991 ); McKenzie et al., Oncogene 4:543-548 (1989 ); Maier et al., Cancer Res. 51:5361-5369 (1991 ); Bacus et al., Molecular Carcinogenesis 3:350-362 (1990 ); Stancovski et al., PNAS (USA) 88:8691-8695 (1991 ); Bacus et al., Cancer Research 52:2580-2589 (1992 ); Xu et al., Int. J.
  • the anti-VEGF antibodies may, for example, comprise the following sequences:
  • the anti-VEGF antibody comprises the following V L sequence (SEQ ID NO:20): and the following V H sequence (SEQ ID NO:21):
  • the anti-VEGF antibody comprises the following V L sequence (SEQ ID NO:22): and the following V H sequence (SEQ ID NO:23):
  • the anti-VEGF antibody comprises the following V L sequence (SEQ ID NO:24): the following V H sequence (SEQ ID NO:25):
  • the humanized anti-CD11a antibody efalizumab or Raptiva ® ( U.S. Patent No. 6,037,454) received marketing approval from the Food and Drug Administration on October 27, 2003 for the treatment for the treatment of psoriasis.
  • One embodiment provides for an anti-human CD11a antibody comprising the V L and V H sequences of HuMHM24 below:
  • the anti-human CD11a antibody may comprise the V H of SEQ ID NO:27 and the full length L chain of HuMHM24 having the sequence of: or the L chain above with the H chain having the sequence of:
  • Antibodies to the DR5 receptor (anti-DR5) antibodies can also be produced in accordance with the present invention.
  • Such anti-DR5 antibodies specifically include all antibody variants disclosed in PCT Publication No. WO 2006/083971 , such as the anti-DR5 antibodies designated Apomabs 1.1, 2.1, 3.1, 4.1, 5.1, 5.2, 5.3 , 6.1, 6.2, 6.3, 7.1, 7.2, 7.3,8.1, 8.3, 9.1, 1.2, 2.2, 3.2, 4.2, 5.2, 6.2, 7.2, 8.2, 9.2, 1.3, 2.2, 3.3, 4.3, 5.3, 6.3, 7.3, 8.3, 9.3, and 25.3, especially Apomab 8.3 and Apomab 7.3, preferably Apomab 7.3.
  • the entire content of WO 2006/083971 is hereby expressly incorporated by reference.
  • tissue plasminogen activators such as human tissue plasminogen activator (htPA, alteplase, ACTIVASE ® ), a thrombolytic agent for the treatment of myocardial infarction
  • htPA tissue plasminogen activator
  • ACTIVASE ® tissue plasminogen activator
  • TNKase TM a ht-PA variant with extended half-life and fibrin specificity for single-bolus administration
  • rhGH, somatropin, NUTROPIN ® , PROTROPIN ® recombinant human growth hormone
  • DNase I recombinant human deoxyribonuclease I
  • disulfide-containing biologically important proteins include growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor, and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage inflammatory protein (MIP-1-alpha);
  • ILs interleukins
  • IL-1 interleukins
  • superoxide dismutase superoxide dismutase
  • T-cell receptors surface membrane proteins
  • decay accelerating factor viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory proteins; integrins such as CD11a, CD11b, CD11c, CD18, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as HER2, HER3 or HER4 receptor; and fragments of any of the above-listed polypeptides.
  • the antibodies and other recombinant proteins herein can be produced by well known techniques of recombinant DNA technology.
  • the skilled practitioner could generate antibodies directed against an antigen of interest, e.g ., using the techniques described below.
  • the antibody herein is directed against an antigen of interest.
  • the antigen is a biologically important polypeptide and administration of the antibody to a mammal suffering from a disease or disorder can result in a therapeutic benefit in that mammal.
  • antibodies directed against nonpolypeptide antigens are also contemplated.
  • the antigen is a polypeptide, it may be a transmembrane molecule ( e.g. receptor) or ligand such as a growth factor.
  • Exemplary antigens include those proteins described in section (3) below.
  • Exemplary molecular targets for antibodies encompassed by the present invention include CD proteins such as CD3, CD4, CD8, CD19, CD20, CD22, CD34, CD40; members of the ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-1, Mac1, p150,95, VLA-4, ICAM-1, VCAM and ⁇ v/ ⁇ 3 integrin including either ⁇ or ⁇ subunits thereof (e.g.
  • anti-CD11a, anti-CD18 or anti-CD11b antibodies growth factors such as VEGF; IgE; blood group antigens; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C, or any of the other antigens mentioned herein.
  • Antigens to which the antibodies listed above bind are specifically included within the scope herein.
  • Soluble antigens or fragments thereof, optionally conjugated to other molecules, can be used as immunogens for generating antibodies.
  • immunogens for transmembrane molecules, such as receptors, fragments of these (e.g. the extracellular domain of a receptor) can be used as the immunogen.
  • transmembrane molecules such as receptors
  • fragments of these e.g. the extracellular domain of a receptor
  • cells expressing the transmembrane molecule can be used as the immunogen.
  • Such cells can be derived from a natural source (e.g. cancer cell lines) or may be cells which have been transformed by recombinant techniques to express the transmembrane molecule.
  • a protein that is immunogenic in the species to be immunized e.g., keyhole limpet hemocyanin, serum albumin, bovine thyrog
  • Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, e.g., 100 ⁇ g or 5 ⁇ g of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites.
  • the animals are boosted with 1/5 to 1/10 the original amount of antigen or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites.
  • Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
  • the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent.
  • Conjugates also can be made in recombinant cell culture as protein fusions.
  • aggregating agents such as alum are suitably used to enhance the immune response.
  • Monoclonal antibodies may be made using the hybridoma method first described by Kohler et al., Nature, 256:495 (1975 ), or may be made by recombinant DNA methods ( U.S. Patent No. 4,816,567 ).
  • a mouse or other appropriate host animal such as a hamster or macaque monkey
  • lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
  • lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell ( Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press. 1986 )).
  • the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA.
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies ( Kozbor, J. Immunol., 133:3001 (1984 ); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987 )).
  • Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • hybridoma cells After hybridoma cells are identified that produce antibodies of the desired specificity. affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods ( Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986 )). Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium.
  • the hybridoma cells may be grown in vivo as ascites tumors in an animal.
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, Protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • immunoglobulin purification procedures such as, for example, Protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • Protein A chromatography procedure described herein is used.
  • DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g ., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences ( U.S. Patent No. 4,816,567 ; Morrison, et al., Proc. Natl Acad. Sci. USA, 81:6851 (1984 )), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
  • non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.
  • monoclonal antibodies can be isolated from antibody phage libraries generated using the techniques described in McCafferty et al., Nature, 348:552-554 (1990 ). Clackson et al., Nature, 352:624-628 (1991 ) and Marks et al., J. Mol. Biol., 222:581-597 (1991 ) describe the isolation of murine and human antibodies, respectively, using phage libraries.
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers ( Jones et al., Nature, 321:522-525 (1986 ); Riechmann et al., Nature, 332:323-327 (1988 ); Verhoeyen et al., Science, 239:1534-1536 (1988 )), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized” antibodies are chimeric antibodies ( U.S. Patent No.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • variable domains both light and heavy
  • sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable-domain sequences.
  • the human sequence which is closest to that of the rodent is then accepted as the human FR for the humanized antibody ( Sims et al., J. Immunol., 151:2296 (1993 )).
  • Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies ( Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992 ); Presta et al., J. Immnol., 151:2623 (1993 )).
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences.
  • Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • the CDR residues are directly and most substantially involved in influencing antigen binding.
  • transgenic animals e.g., mice
  • transgenic animals e.g., mice
  • J H antibody heavy-chain joining region
  • Human antibodies can also be derived from phage-display libraries ( Hoogenboom et al., J. Mol. Biol., 227:381 (1991 ); Marks et al., J. Mol. Biol., 222:581-597 (1991 ); Vaughan et al., Nature Biotech 14:309 (1996 )).
  • antibody fragments Traditionally, these fragments were derived via proteolytic digestion of intact antibodies (see, e.g., Morimoto et al., Journal of Biochemical and Biophysical Methods 24:107-117 (1992 ) and Brennan et al., Science, 229:81 (1985 )). However, these fragments can now be produced directly by recombinant host cells. For example, the antibody fragments can be isolated from the antibody phage libraries discussed above. Alternatively, Fab'-SH fragments can be directly recovered from E. coli and chemically coupled to form F(ab') 2 fragments ( Carter et al., Bio/Technology 10:163-167 (1992 )).
  • F(ab') 2 fragments can be isolated directly from recombinant host cell culture.
  • Other techniques for the production of antibody fragments will be apparent to the skilled practitioner.
  • the antibody of choice is a single chain Fv fragment (scFv) (see WO 93/16185 ).
  • Multispecific antibodies have binding specificities for at least two different antigens. While such molecules normally will only bind two antigens (i.e. bispecific antibodies, BsAbs), antibodies with additional specificities such as trispecific antibodies are encompassed by this expression when used herein.
  • bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities ( Millstein et al., Nature, 305:537-539 (1983 )). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in WO 93/08829 , and in Traunecker et al., EMBO J., 10:3655-3659 (1991 ).
  • the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
  • the preferred interface comprises at least a part of the C H 3 domain of an antibody constant domain.
  • one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g . tyrosine or tryptophan).
  • Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones ( e.g . alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
  • Bispecific antibodies include cross-linked or "heteroconjugate" antibodies.
  • one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
  • Such antibodies have, for example, been proposed to target immune system cells to unwanted cells ( US Patent No. 4,676,980 ), and for treatment of HIV infection ( WO 91/00360 , WO 92/200373 , and EP 03089 ).
  • Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in US Patent No. 4,676,980 , along with a number of cross-linking techniques.
  • bispecific antibodies can be prepared using chemical linkage.
  • Brennan et al., Science, 229: 81 (1985 ) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab') 2 fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation.
  • the Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
  • One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody.
  • the bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
  • bispecific antibodies have been produced using leucine zippers.
  • the leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion.
  • the antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers.
  • the fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • V H and V L domains of one fragment are forced to pair with the complementary V L and V H domains of another fragment, thereby forming two antigen-binding sites.
  • sFv single-chain Fv
  • the antibodies can be "linear antibodies” as described in Zapata et al., Protein Eng. 8(10):1057-1062 (1995 ). Briefly, these antibodies comprise a pair of tandem Fd segments (V H -C H 1-V H -C H 1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
  • Antibodies with more than two valencies are contemplated.
  • trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147: 60 (1991 ).
  • the simplest and most straightforward immunoadhesin design combines the binding domain(s) of the adhesin (e.g. the extracellular domain (ECD) of a receptor) with the hinge and Fc regions of an immunoglobulin heavy chain.
  • ECD extracellular domain
  • nucleic acid encoding the binding domain of the adhesin will be fused C-terminally to nucleic acid encoding the N-terminus of an immunoglobulin constant domain sequence, however N-terminal fusions are also possible.
  • the encoded chimeric polypeptide will retain at least functionally active hinge, C H 2 and C H 3 domains of the constant region of an immunoglobulin heavy chain. Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the C H 1 of the heavy chain or the corresponding region of the light chain.
  • the precise site at which the fusion is made is not critical; particular sites are well known and may be selected in order to optimize the biological activity, secretion, or binding characteristics of the immunoadhesin.
  • the adhesin sequence is fused to the N-terminus of the Fc domain of immunoglobulin G I (IgG I ). It is possible to fuse the entire heavy chain constant region to the adhesin sequence. However, more preferably, a sequence beginning in the hinge region just upstream of the papain cleavage site which defines IgG Fc chemically (i.e. residue 216, taking the first residue of heavy chain constant region to be 114), or analogous sites of other immunoglobulins is used in the fusion.
  • the adhesin amino acid sequence is fused to (a) the hinge region and C H 2 and C H 3 or (b) the C H 1, hinge, C H 2 and C H 3 domains, of an IgG heavy chain.
  • the immunoadhesins are assembled as multimers, and particularly as heterodimers or heterotetramers.
  • these assembled immunoglobulins will have known unit structures.
  • a basic four chain structural unit is the form in which IgG, IgD, and IgE exist.
  • a four chain unit is repeated in the higher molecular weight immunoglobulins; IgM generally exists as a pentamer of four basic units held together by disulfide bonds.
  • IgA globulin, and occasionally IgG globulin may also exist in multimeric form in serum. In the case of multimer, each of the four units may be the same or different.
  • the adhesin sequences can be inserted between immunoglobulin heavy chain and light chain sequences, such that an immunoglobulin comprising a chimeric heavy chain is obtained.
  • the adhesin sequences are fused to the 3' end of an immunoglobulin heavy chain in each arm of an immunoglobulin, either between the hinge and the C H 2 domain, or between the C H 2 and C H 3 domains. Similar constructs have been reported by Hoogenboom, et al., Mol. Immunol. 28:1027-1037 (1991 ).
  • an immunoglobulin light chain might be present either covalently associated to an adhesin-immunoglobulin heavy chain fusion polypeptide, or directly fused to the adhesin.
  • DNA encoding an immunoglobulin light chain is typically coexpressed with the DNA encoding the adhesin-immunoglobulin heavy chain fusion protein.
  • the hybrid heavy chain and the light chain will be covalently associated to provide an immunoglobulin-like structure comprising two disulfide-linked immunoglobulin heavy chain-light chain pairs.
  • Immunoadhesins are most conveniently constructed by fusing the cDNA sequence encoding the adhesin portion in-frame to an immunoglobulin cDNA sequence.
  • fusion to genomic immunoglobulin fragments can also be used (see, e.g. Aruffo et al., Cell 61:1303-1313 (1990 ); and Stamenkovic et al., Cell 66:1133-1144 (1991 )).
  • the latter type of fusion requires the presence of Ig regulatory sequences for expression.
  • cDNAs encoding IgG heavy-chain constant regions can be isolated based on published sequences from cDNA libraries derived from spleen or peripheral blood lymphocytes, by hybridization or by polymerase chain reaction (PCR) techniques.
  • the cDNAs encoding the "adhesin" and the immunoglobulin parts of the immunoadhesin are inserted in tandem into a plasmid vector that directs efficient expression in the chosen host cells.
  • Materials and devices used in the experiments described in the experimental examples include: stainless steel vials (mini-tanks, Flow Components, Dublin, CA; short (50 cc) and tall (55 cc)); dialysis tubing (Spectra/Por, 6-8000 MWCO, cat. # 132645), 0.22 ⁇ m filter (Millipore Millipak Gamma Gold cat. # MPGL04GH2); phosphate buffered saline (PBS, EMD, cat. # 6506); ethylenediaminetetraacetic acid (EDTA, Sigma, cat. # E4884); ⁇ -nicotinamide adenine dinucleotide phosphate (NADPH, Calbiochem, cat.
  • stainless steel vials mini-tanks, Flow Components, Dublin, CA; short (50 cc) and tall (55 cc)
  • dialysis tubing Spectra/Por, 6-8000 MWCO, cat. # 132645), 0.22 ⁇ m filter
  • Trx (Sigma, cat. # T8690); TrxR (Sigma, cat. # T9698). All chemicals and reagents were used as received with no further purification. Stock solutions of EDTA (250 mM, pH 7.5), CuSO 4 (10 mM), ATG (30 mM), ATM (30 mM), NADPH (75 mM), G6P (300 mM) were prepared for use in the mini-tank time course studies.
  • Complete lysis of CCF was achieved by high pressure homogenization using a Microfluidics HC-8000 homogenizer.
  • the pressure regulator of the instrument was set to 4,000-8,000 psi, and the CCF was pulled in through the homogenizer to obtain complete cell lysis (membrane breakage) after a single pass.
  • the CCF homogenate was collected once water was purged through the system.
  • the homogenate was transferred to centrifuge bottles and centrifuged in a Sorval RC-3B rotor centrifuge at 4,500 rpm for 30 minutes at 20 °C.
  • centrate was decanted and then depth filtered followed by 0.22 ⁇ m sterile filtration using a peristaltic pump with silicon tubing to generate the final HCCF from the homogenized CCF (100% cell lysis).
  • the CCF was centrifuged straight from the fermentor without any homogenization and then the centrate was filtered with a sterile 0.22 ⁇ m filter to generate the HCCF.
  • a laminar flow hood was used in handling all mini-tanks and all materials used in the HCCF incubation experiments were either autoclaved or rinsed using 70% isopropanol to minimize bacterial contamination.
  • a dialysis experiment was carried out in order to determine whether the components causing reduction of ocrelizumab were small molecules or macromolecules (i.e. enzymes).
  • a sample of 3 mL of purified and formulated ocrelizumab (30.2 mg/mL) was dialyzed against 1 L of phosphate buffered saline (PBS, 10 mM pH 7.2) for 24 hours and the PBS was changed after 8 hours. The concentration of the ocrelizumab sample was then adjusted to 1 mg/mL using the absorbance at 280 nm. Aliquots were stored at -70 °C prior to use. Dialysis tubing was hydrated overnight in a 0.05% azide solution and rinsed with sterile water prior to use.
  • PBS phosphate buffered saline
  • the HCCF obtained from homogenization of CCF from a 3-L fermentor was thawed and filtered through a 0.22 ⁇ m Millipak filter using a peristaltic pump.
  • Six short mini-tanks were filled with 30 mL of HCCF each.
  • 500 ⁇ L of ocrelizumab sample in sealed dialysis tubing was added.
  • the mini-tanks were sealed and loaded into a bench top mixer (Barnstead Lab-Line MAX Q 4000) operating at 35 rpm and ambient temperature.
  • one mini-tank was removed from the mixer, and aliquots of the HCCF (in the mini-tank) and ocrelizumab sample (in the dialysis bag) were taken and stored at -70 °C until analyzed with the free thiol assay and the Bioanalyzer assay (described below).
  • a tall mini-tank was filled with 27 mL of HCCF.
  • various reagents NADPH, G6P, inhibitors of G6PD or TrxR
  • PBS 10 mM pH 7.2
  • the mini-tanks were sealed and loaded into a bench top mixer running at 35 rpm and ambient temperature.
  • the exteriors of the mini-tanks were sterilized with 70% IPA and opened in a laminar flow hood for the removal of an aliquot.
  • the mini-tanks were then re-sealed and loaded back into the bench top mixer. All aliquots were stored at -70 °C until analyzed with the free thiol assay and Bioanalyzer assay (described below).
  • TrxR rat liver
  • lyophilized Trx human was reconstituted with PBS (10 mM, pH 7.2) yielding a 500 ⁇ M solution.
  • a solution of 20 mM NADPH and 10 mM ATG and ATM solutions were prepared in water.
  • a standard curve using GSH was generated in PBS (10 mM, pH 6.0 ⁇ 0.05). From a 110 mM GSH solution, standards were prepared at concentrations of 0, 5.5, 11, 22, 44, 55, 110 and 550 ⁇ M through serial dilution. From an acetonitrile stock solution of mBB (10 mM stored at -20 °C), a 100 ⁇ M solution of mBB was prepared in PBS (10 mM, pH 10.0 ⁇ 0.05) and stored away from light.
  • a stock solution of either 250 mM EDTA or 50 mM CuSO 4 was added to the CCF prior to homogenization to evaluate a range of final concentrations to prevent antibody disulfide reduction.
  • these solutions were then mixed with the HCCF generated from the non-homogenized CCF (also containing EDTA or CuSO 4 ) in order to dilute and decrease the total level of cell lysis to below the 100% maximum.
  • a stock solution of 1 M acetic acid was added to a final blended HCCF solution (homogenized CCF and non-homogenized CCF) to decrease the pH of the solution to prevent antibody disulfide reduction.
  • each HCCF solution (containing EDTA, CuSO 4 , acetic acid, or no addition for the control) was held in a 50 mL 316L stainless steel vial.
  • the vial was sealed with a clamp, and the solution was not aerated or agitated.
  • the vial was stored at room temperature (18 - 22 °C). At pre-determined time points, the solution was removed and purified over a lab scale protein A affinity resin.
  • Antibody in harvested cell culture fluid samples can be captured and purified using a specific affinity chromatography resin.
  • Protein A resin (Millipore, Prosep-vA High Capacity) was selected as the affinity resin for antibody purification.
  • the resin was packed in a 0.66 cm inner diameter glass column (Omnifit ® ) with a 14 cm bed height resulting in a 4.8 mL final column volume. Chromatography was performed using an AKTA Explorer 100 chromatography system (GE Healthcare).
  • the resin was exposed to buffers and HCCF at a linear flow rate between 350-560 cm/hr.
  • the resin was equilibrated with 25 mM Tris, 25 mM NaCl, 5 mM EDTA, pH 7.1.
  • the resin was loaded between 5-15 mg antibody per mL of resin.
  • the antibody concentration in the HCCF was determined using an immobilized protein A HPLC column (Applied Biosystems, POROS A). After loading, the resin was washed with 25 mM Tris, 25 mM NaCl, 5 mM EDTA, 0.5 M TMAC, pH 7.1, and then the antibody was eluted using 0.1M acetic acid, pH 2.9.
  • Elution pooling was based on UV absorbance at 280 nm measured inline after the column.
  • the purified elution pools were pH-adjusted using 1 M Sodium HEPES to pH 5.0-5.5. After regeneration of the resin with 0.1M phosphoric acid, the same or similar packed resins were used for subsequent purification of other HCCF solutions.
  • the antibody concentration in the purified protein A pool was measured using UV spectrometry at 280 nm.
  • the purified protein A elution pools were analyzed by the Bioanalyzer assay to quantitate the percentage of intact antibody at 150 kDa molecular weight.
  • a dialysis experiment was designed and carried out to determine if the reduction of ocrelizumab was caused by small reducing molecules or macromolecules (e.g ., enzymes).
  • purified intact ocrelizumab was placed in a dialysis bag with a molecular weight cut off (MWCO) of 7000 and incubated the dialysis bag in HCCF containing ocrelizumab in a stainless steel mini-tank.
  • MWCO molecular weight cut off
  • Trx system was tested for its ability to reduce ocrelizumab in vitro by incubating intact ocrelizumab with Trx, TrxR, and NADPH.
  • the Bioanalyzer results indicate that ocrelizumab was reduced in vitro by the Trx system ( Figure 5 ).
  • the rate of reduction in this in vitro system appears to be slower than that in the HCCF (for example when compared to the reduction shown in Figure 2 ). This is likely due to lower concentrations of the enzymes (Trx and Trx-R) and/or the buffer system used in the in vitro reaction because reaction rate of Trx system is dependent on both the enzyme concentrations and buffer systems.
  • Cupric sulfate is known for its ability to provide oxidizing redox potential and has been used in the cell culture processes to minimize free thiol (i.e., minimize unpaired cysteine) levels in recombinant antibody molecules (Chaderjian et al., 2005, supra). Cupric sulfate was tested for efficacy in inhibiting the Trx system in vitro and the subsequent reduction of ocrelizumab. In this in vitro reduction experiment, the buffer system was changed from PBS to histidine sulfate to avoid the formation of insoluble Cu 3 (PO 4 ) 2 .
  • FIG 8 shows that ocrelizumab was readily reduced by the Trx system in the histidine sulfate buffer (even faster than in PBS buffer).
  • the addition of CuSO 4 to this reaction clearly inhibits the ocrelizumab reduction ( Figure 9 ).
  • TrxR aurothioglucose
  • ATM aurothiomalate
  • Trx system was active in the HCCF and reduced ocrelizumab as observed in the manufacturing runs resulting in reduced antibody molecules or in the lab scale experiments, both gold compounds (ATG and ATM) should be able to inhibit the reduction of ocrelizumab in HCCF.
  • Figure 10 shows that ocrelizumab was readily reduced in an HCCF from homogenized CCT generated from a 3-L fermentor after a period of incubation. However, the ocrelizumab reduction event was completely inhibited when either 1 mM ATG or ATM was added to the HCCF ( Figures 11 and 12 ). These results demonstrated that the Trx system is active in the HCCF and is directly responsible for the reduction of ocrelizumab.
  • the reduction of disulfides by the Trx system requires the reducing equivalents from NADPH ( Figure 4 ).
  • the main cellular metabolic pathway that provides NADPH for all reductive biosynthesis reactions is the pentose phosphate pathway.
  • the enzymes in this pathway must be still active in the HCCF in order to keep the Trx system active.
  • the first step in the pentose phosphate pathway (catalyzed by G6PD) must be active to reduce NADP + to NADPH while converting G6P to 6-phosphogluconolactone.
  • G6P is most likely produced from glucose and adenosine 5'-triphosphate (ATP) by the hexokinase activity in HCCF.
  • ATP adenosine 5'-triphosphate
  • HCCF The reducing activity in the HCCF appeared to be transitory in some cases and may be inhibited over time under certain storage conditions or after multiple freeze/thaw cycles. HCCF that has fully lost reducing activity provided an opportunity to explore the role of NADPH and G6P in the reduction of ocrelizumab by Trx system.
  • the hexokinase catalyzes the transfer of phosphate group from Mg2+-ATP to glucose, a reaction that requires the complexation of Mg2+ with ATP (Hammes & Kochavi, 1962a & 1962b, supra). Since EDTA is a metal ion chelator, especially for Mg2+, it can be an effective inhibitor of hexokinase. The observation that an excess amount of EDTA can effectively block the reduction indicates the involvement of hexokinase (i.e. providing G6P) in the mechanism of ocrelizumab reduction.
  • EDTA blocks the reduction of ocrelizumab by eliminating the hexokinase activity and thereby reducing the G6P level available for G6PD, and subsequently the NADPH level available for the Trx system.
  • EDTA is every effective in blocking the reduction of ocrelizumab in fresh HCCF, it was unable to prevent the reduction of ocerlizumab in the beta run HCCF in which the Trx system activity was lost then reactivated by the addition of G6P.
  • the reduction of ocrelizumab was observed in an HCCF incubation experiment in which 5 mM G6P and 20 mM EDTA (final concentrations) were added to the beta run HCCF that had fully lost reducing activity ( Figure 18 ).
  • no reduction was seen in the control incubation experiment in which no G6P and EDTA were added.
  • the EDTA used in this manner may therefore inhibit neither the Trx system nor the G6PD, and may function as an inhibitor for hexokinase, which produces the G6P for the G6PD. Without G6P, the Trx system would not be supplied with the necessary NADPH for activity.
  • Dehydroepiandrosterone as well as other similar G6PD inhibitors, effectively blocks G6PD activity (Gordon et al., 1995, supra). G6PD inhibitors also prevent the reduction of an antibody in HCCF, for example, ocrelizumab, by blocking the generation of NADPH. The ability of DHEA to inhibit the reduction of orcelizumab is demonstrated in an HCCF incubation experiment. Adding DHEA to a HCCF prevents antibody reduction.
  • DHEA is typically used in the concentration range from about 0.05 mM to about 5 mM. DHEA is also typically used in the concentration range from about 0.1 mM to about 2.5 mM.
  • HCCFs Four different HCCFs were stored and held in the stainless steel vials. The solutions were similar in the amount of cell lysis, which were generated by diluting HCCF from homogenized CCF with HCCF from non-homogenized CCF. For example, 150 mL of the first lysed solution was mixed with 50 mL of the second solution, respectively.
  • the four HCCF mixtures evaluated in this study contained either: (1) 20 mM EDTA, (2) 30 ⁇ M CuSO 4 , (3) 15 mM acetic acid (pH 5.5), and (4) no chemical inhibitor was added for the control solution.
  • the design of targeted siRNAs or antisense nucleotides to the genes as found in CHO cells may be done by using publicly available sequences such as those for E. coli thioredoxin TrxA (SEQ ID NO:30), E. coli thioredoxin reductase TrxB (SEQ ID NO:31); mouse thioredoxin 1 (SEQ ID NO:32), mouse thioreodoxin 2 (SEQ ID NO:33), mouse thioredoxin reductase 1 (SEQ ID NO:34), and mouse thioredoxin reductase 2 (SEQ ID NO:35).
  • E. coli thioredoxin TrxA SEQ ID NO:30
  • E. coli thioredoxin reductase TrxB SEQ ID NO:31
  • mouse thioredoxin 1 SEQ ID NO:32
  • mouse thioreodoxin 2 SEQ ID NO:33
  • mouse thioredoxin 1 The sequence of mouse thioredoxin 1 is:
  • mouse thioreodoxin 2 The sequence of mouse thioreodoxin 2 is:
  • mouse thioredoxin reductase 1 The sequence of mouse thioredoxin reductase 1 is:
  • mouse thioredoxin reductase 2 The sequence of mouse thioredoxin reductase 2 is:
  • TrxR rat liver
  • lyophilized Trx human was reconstituted with PBS (10 mM, pH 7.2) yielding a 500 ⁇ M solution.
  • a solution of 20 mM NADPH and 10 mM ATG and ATM solutions were prepared in water.
  • reaction buffer (10 mM histidine, 10 mM Na2SO4, 137 mM NaCl, 2.5 mM KCl, pH 7.0), 25 ⁇ L NADPH, 16 ⁇ L formulated ocrelizumab solution (30.2 mg/mL) and 5 ⁇ L Trx were gently mixed.
  • the reaction was initiated by the addition of 17.5 ⁇ L TrxR.
  • the reaction was incubated at room temperature for 24 hours. Aliquots of 20 ⁇ L were taken at each sampling time-point and stored at -70 °C until analyzed by the Bioanalyzer assay.
  • Figure 24 shows a digital gel-like image from Bioanalyzer analysis (each lane representing a time point) showing that incubation of intact ocrelizumab ("2H7," a humanized anti-CD20 antibody, referred to as "Variant A" above) (1 mg/mL) with 0.1 ⁇ M TrxR (rat liver), 5 ⁇ M Trx (human) and 1 mM NADPH in 10 mM histidine sulfate buffer results in the reduction of ocrelizumab in less than one hour.
  • 2H7 a humanized anti-CD20 antibody
  • Aurothioglucose was added to the ocrelizumab mixture described above, at the following concentrations: 1 mM; 0.6 ⁇ M (6:1 ATG:TrxR); 0.4 ⁇ M (4:1 ATG:TrxR); and 0.2 ⁇ M (2:1 ATG:TrxR).
  • aurothioglucose added at concentrations 1 mM, 0.6 ⁇ M, and 0.4 ⁇ M effectively inhibits the reduction of ocrelizumab by the thioredoxin system.
  • aurothioglucose added at a concentration of 0.2 ⁇ M cannot inhibit ocrelizumab reduction after 24 hours.
  • ATM Aurothiomalate
  • CuSO 4 was added to the ocrelizumab mixture described above, at concentrations of 20 ⁇ M (4:1 Cu 2+ :Trx) ; 10 ⁇ m (2:1 Cu 2+ :Trx); and 5 ⁇ M (1:1 Cu 2+ :Trx).
  • CuSO 4 effectively inhibits thioredoxin-induced reduction of ocrelizumab at concentrations of 20 ⁇ M and 10 ⁇ M ( Figures 31 and 32 ), but the 5 ⁇ M concentration is insufficient to result in a complete inhibition of reduction ( Figure 33 ).
  • Cystamine was added to the ocrelizumab mixture describe above at the following concentrations: 532 ⁇ M (20:1 cystamine:2H7 (Variant A) disulfide); 266 ⁇ M (10:1 cystamine:2H7 (Variant A) disulfide); 133 ⁇ M (5:1 cystamine:2H7 disulfide); and 26.6 ⁇ M (1:1 cystamine:2H7 (Variant A) disulfide).
  • cystamine effectively inhibits thioredoxin-induced reduction of ocrelizumab at concentrations of 532 ⁇ M (20:1 cystamine:2H7 (Variant A) disulfide) and 266 ⁇ M (10:1 cystamine:2H7 (Variant A)) ( Figures 34 and 35 ) but the 133 ⁇ M (5:1 cystamine:2H7 (Variant A) disulfide) and 26.6 ⁇ M (1:1 cystamine:2H7 (Variant A) disulfide) concentrations are insufficient to inhibit the reduction of ocrelizumab after 24 hours ( Figures 36 and 37 ).
  • Cystine was added to the ocrelizumab mixture described above at a concentration of 2.6 mM. As shown in Figure 38 , at this concentration cystine effectively inhibits reduction of ocrelizumab by the thioredoxin system. It is noted that the minimum effective concentration of cystine (just as the effective minimum concentration of other inhibitors) depends on the actual circumstances, and might be different for different proteins, such as antibodies, and might vary depending on the timing of addition. Thus, for example, if cystine is added pre-lysis, the minimum effective concentration for antibody 2H7 (Variant A) is about 1.3 mM, for Apomab about 1 mM and for antibody Variant C about 4.5 mM.
  • the minimum effective concentration typically is somewhat higher, and is about 5.2 mM for 2H7 (Variant A), 6 mM for Apomab and 9 mM for antibody Variant C.
  • the minimum effective inhibitory concentration is about 40x of the antibody concentration (in ⁇ M).
  • GSSG was added to the ocrelizumab mixture described above at a concentration of 2.6 mM. As shown in Figure 39 , at this concentration GSSG effectively inhibits reduction of ocrelizumab by the thioredoxin system. It is noted, however, that the minimum effective concentration of oxidize glutathione (just as that of the other inhibitors) depends on the actual circumstances, such as, for example, on the nature of the protein (e.g. antibody) produced and the timing of addition. For example, for antibody 2H7 (Variant A) the minimum effective concentration is about 1.3 mM for addition prior to lysis.
  • Figure 40 shows a digital gel-like image from Bioanalyzer analysis (each lane representing a time point) showing that incubation of intact ocrelizumab ("2H7," a humanized anti-CD20 antibody, Variant A) (1 mg/mL) with 10 ⁇ g/mL hexokinase, 50 ⁇ g/mL glucose-6-phosphate dehydrogenase, 5 ⁇ M thioredoxin, 0.1 ⁇ M thoredoxin reductase, 2 mM glucose, 0.6 mM ATP, 2 mM Mg 2+ , and 2 mM NADP in 50 mM histidine sulfate buffered at pH 7.38 results in the reduction of ocrelizumab in about one hour. Addition of 0.1 mM HDEA, a known glucose-6-phosphate dehydrogenase inhibitor does not inhibit the reduction.
  • 2H7 a humanized anti-CD20 antibody, Variant A

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP23172637.3A 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides Pending EP4245766A3 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US94867707P 2007-07-09 2007-07-09
EP08781481.0A EP2188302B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons disulfure au cours de la production recombinante de polypeptides
EP23153140.1A EP4219522A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP19181777.4A EP3597659B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
PCT/US2008/069395 WO2009009523A2 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons disulfure au cours de la production recombinante de polypeptides
EP17196350.7A EP3327026B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP12178200.7A EP2586788B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides

Related Parent Applications (7)

Application Number Title Priority Date Filing Date
EP17196350.7A Division EP3327026B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP08781481.0A Division EP2188302B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons disulfure au cours de la production recombinante de polypeptides
EP23153140.1A Division EP4219522A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP23153140.1A Previously-Filed-Application EP4219522A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP23153140.1A Division-Into EP4219522A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP19181777.4A Division EP3597659B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP12178200.7A Division EP2586788B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides

Publications (3)

Publication Number Publication Date
EP4245766A2 true EP4245766A2 (fr) 2023-09-20
EP4245766A3 EP4245766A3 (fr) 2024-01-17
EP4245766A9 EP4245766A9 (fr) 2024-01-24

Family

ID=39791340

Family Applications (8)

Application Number Title Priority Date Filing Date
EP23172637.3A Pending EP4245766A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP23214759.5A Pending EP4335863A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP17196350.7A Active EP3327026B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP08781481.0A Active EP2188302B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons disulfure au cours de la production recombinante de polypeptides
EP24160370.3A Pending EP4365189A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP23153140.1A Pending EP4219522A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP12178200.7A Revoked EP2586788B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP19181777.4A Active EP3597659B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides

Family Applications After (7)

Application Number Title Priority Date Filing Date
EP23214759.5A Pending EP4335863A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP17196350.7A Active EP3327026B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP08781481.0A Active EP2188302B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons disulfure au cours de la production recombinante de polypeptides
EP24160370.3A Pending EP4365189A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP23153140.1A Pending EP4219522A3 (fr) 2007-07-09 2008-07-08 Prévention de la réduction de liaisons disulfures pendant la production recombinante de polypeptides
EP12178200.7A Revoked EP2586788B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides
EP19181777.4A Active EP3597659B1 (fr) 2007-07-09 2008-07-08 Prévention de la réduction des liaisons de disulfure pendant la production recombinante de polypeptides

Country Status (24)

Country Link
US (14) US20090053786A1 (fr)
EP (8) EP4245766A3 (fr)
JP (5) JP5687057B2 (fr)
KR (6) KR101851580B1 (fr)
CN (3) CN101932591B (fr)
AU (2) AU2008275229B2 (fr)
BR (1) BRPI0812603B1 (fr)
CA (2) CA3113365A1 (fr)
DE (1) DE17196350T1 (fr)
DK (2) DK3327026T3 (fr)
ES (4) ES2751022T3 (fr)
FI (1) FI3597659T3 (fr)
HR (3) HRP20230461T3 (fr)
HU (4) HUE046992T2 (fr)
IL (6) IL202934B (fr)
LT (2) LT3327026T (fr)
MX (2) MX354993B (fr)
PL (4) PL3597659T3 (fr)
PT (2) PT3327026T (fr)
SG (3) SG10202005450PA (fr)
SI (4) SI2188302T1 (fr)
TR (1) TR201802088T4 (fr)
TW (4) TW202124409A (fr)
WO (1) WO2009009523A2 (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2380911T1 (en) 2003-11-05 2018-07-31 Roche Glycart Ag ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CA2842959A1 (fr) 2006-09-13 2008-03-20 Abbvie Inc. Ameliorations a la culture de cellules
CA3113365A1 (fr) 2007-07-09 2009-01-15 Genentech, Inc. Prevention de la reduction des liaisons disulfure au cours de la production recombinante de polypeptides
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
CA2738499A1 (fr) 2008-10-20 2010-04-29 Abbott Laboratories Inactivation virale pendant la purification d'anticorps
MX2011004200A (es) 2008-10-20 2011-05-24 Abbott Lab Aislamento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
DK2424889T3 (en) 2009-04-30 2015-11-02 Ablynx Nv Process for the preparation of domain antibodies
MX346002B (es) * 2009-06-17 2017-03-01 Abbvie Biotherapeutics Inc Anticuerpos anti-vegf y sus usos.
MX2012001742A (es) 2009-08-11 2012-03-21 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2513148B1 (fr) * 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anticorps anti-her2 et leurs utilisations
US20130028920A1 (en) * 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
CN101974535B (zh) * 2010-11-03 2012-12-19 北京天广实生物技术股份有限公司 新型抗ErbB2人源化抗体MIL12的制备及其应用
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
EP2646468B1 (fr) 2010-12-01 2018-07-25 AlderBio Holdings LLC Compositions anti-ngf et leur utilisation
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012149197A2 (fr) 2011-04-27 2012-11-01 Abbott Laboratories Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
CN102911265B (zh) * 2011-08-05 2014-02-05 王革 一种人神经生长因子的重组变异体及其制备方法
AR090340A1 (es) * 2012-03-27 2014-11-05 Genentech Inc Operaciones de cosecha mejoradas para proteinas recombinadas
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (fr) 2012-05-24 2013-11-28 Abbvie Inc. Nouvelle purification d'anticorps au moyen de chromatographie à interaction hydrophobe
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (fr) 2012-09-02 2015-07-08 AbbVie Inc. Procédés de contrôle de l'hétérogénéité des protéines
WO2014054744A1 (fr) 2012-10-03 2014-04-10 協和発酵キリン株式会社 Procédé de prévention de la réduction de polypeptide par l'ajout d'acide aminé à un milieu de culture liquide
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CA2905010A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Anticorps humains qui se lient au tnf-alpha et leurs procedes de preparation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
US10398682B2 (en) 2013-07-15 2019-09-03 The Board Of Regents Of The University Of Texas System Methods and compositions to prevent or treat bacterial infections
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR20160088930A (ko) * 2013-12-04 2016-07-26 이뮤노젠 아이엔씨 항체 생산용 조성물 및 항체 생성 방법
US9620278B2 (en) * 2014-02-19 2017-04-11 General Electric Company System and method for reducing partial discharge in high voltage planar transformers
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
US10653794B2 (en) * 2015-08-12 2020-05-19 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
EP4209499B1 (fr) 2015-08-13 2024-08-07 Amgen Inc. Filtration sur profondeur chargée de protéines de liaison à l'antigène
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017181031A2 (fr) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anticorps anti-pacap et leurs utilisations
EP3454890A4 (fr) * 2016-05-10 2020-01-15 MedImmune, LLC Prévention de la réduction des liaisons disulfure de protéines
MX2018013683A (es) * 2016-05-10 2019-06-17 Genentech Inc Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.
CN109496237A (zh) 2016-06-10 2019-03-19 隆扎有限公司 用于稳定化蛋白质的方法
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
CN106366160B (zh) * 2016-10-11 2019-06-14 厦门大学 基于二硫键精准配对构建富含二硫键多肽分子骨架的方法
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
MX2019006072A (es) 2016-11-30 2019-08-14 Oncomed Pharm Inc Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
US20190316096A1 (en) 2016-12-28 2019-10-17 Kyowa Hakko Kirin Co Method for selecting cell
EP3615070A1 (fr) 2017-04-26 2020-03-04 Bristol-Myers Squibb Company Procédés de production d'anticorps qui réduisent au minimum la réduction de liaison disulfure
KR102664829B1 (ko) * 2017-05-09 2024-05-09 브리스톨-마이어스 스큅 컴퍼니 항체 제작 동안 핑크색의 형성을 제어하는 방법
US10913795B2 (en) 2017-05-17 2021-02-09 Immunogen, Inc. Compositions and methods for antibody production
EP3672981A4 (fr) * 2017-08-22 2021-09-15 Biogen MA Inc. Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
TW201923069A (zh) * 2017-10-02 2019-06-16 美商拜耳保健有限責任公司 以亞硒酸鹽防止細胞培養收獲物中雙硫鍵還原之方法
TW201927335A (zh) * 2017-10-02 2019-07-16 美商拜耳保健有限責任公司 防止雙硫鍵於細胞培養收集物中還原之方法
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
CN112074604A (zh) * 2018-05-04 2020-12-11 西格马-奥尔德里奇有限责任公司 具有修饰的宿主细胞蛋白概况的工程改造的细胞
WO2020028616A1 (fr) * 2018-08-02 2020-02-06 Lonza Ltd Procédés de fabrication d'une protéine de recombinaison comprenant une liaison disulfure
BR112021009036A2 (pt) 2018-11-08 2021-08-24 Sutro Biopharma, Inc. Cepas de e coli apresentando um citoplasma oxidativo
EP3947632A1 (fr) 2019-04-01 2022-02-09 The Automation Partnership (Cambridge) Ltd. Procédé de fonctionnement pour un système de culture cellulaire
JP2022542863A (ja) 2019-07-24 2022-10-07 ハー・ルンドベック・アクチエゼルスカベット 抗ｍＧｌｕＲ５抗体及びその使用
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies
CN113480652B (zh) * 2021-07-30 2023-04-07 成都景泽生物制药有限公司 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法
WO2023049687A1 (fr) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Procédés de régulation du taux d'oxygène dissous (do) dans une solution comprenant une protéine recombinante dans un récipient de stockage
WO2024058951A1 (fr) * 2022-09-15 2024-03-21 Sanofi Procédés de détermination de la susceptabilité de réduction de protéine

Citations (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0003089A1 (fr) 1978-01-06 1979-07-25 Bernard David Séchoir pour feuilles imprimées par sérigraphie
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0139383A1 (fr) 1983-08-16 1985-05-02 Zymogenetics, Inc. Méthode pour l'expression de gènes étrangers en Schizosaccharomyces pombe et l'utilisation de ces produits en compositions thérapeutiques, constructions d'ADN et souches transformantes de Schizosaccharomyces pombe utilisables dans une telle méthode et leur préparation
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
EP0183070A2 (fr) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation de levures du genre Pichia
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0244234A2 (fr) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation de trichoderma
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
EP0307247A2 (fr) 1987-09-11 1989-03-15 Genentech, Inc. Méthode pour cultiver des cellules recombinantes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
EP0330191A2 (fr) 1988-02-25 1989-08-30 The General Hospital Corporation ADN encodant CD40
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
EP0394538A1 (fr) 1989-04-28 1990-10-31 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh Cellules de levure du genre schwanniomyces
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
WO1991000357A1 (fr) 1989-06-30 1991-01-10 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
EP0420937A1 (fr) 1988-06-21 1991-04-10 Genentech Inc Compositions therapeutiques pour le traitement de l'infarctus du myocarde.
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1993001161A1 (fr) 1991-07-11 1993-01-21 Pfizer Limited Procede de preparation d'intermediaires de sertraline
WO1993004173A1 (fr) 1991-08-14 1993-03-04 Genentech, Inc. Variantes d'immunoglobulines pour des recepteurs specifiques fc epsilon
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
WO1994000136A1 (fr) 1992-06-30 1994-01-06 Oncologix, Inc. COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION
WO1995003770A1 (fr) 1993-08-02 1995-02-09 The Board Of Trustees Of The Leland Stanford Junior University Procedes de regulation de la population des lymphocytes b
WO1995019181A1 (fr) 1994-01-18 1995-07-20 Genentech, Inc. PROCEDE DE TRAITEMENT DE LA PARASITOSE A L'AIDE D'ANTAGONISTES DE L'IgE
WO1995023865A1 (fr) 1994-03-03 1995-09-08 Genentech, Inc. Anticorps monoclonaux anti-il-8 pour le traitement des troubles
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1996027011A1 (fr) 1995-03-01 1996-09-06 Genentech, Inc. Procede d'obtention de polypeptides heteromultimeriques
WO1996030046A1 (fr) 1995-03-30 1996-10-03 Genentech, Inc. Antagonistes de facteurs de croissance des cellules endotheliales vasculaires
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
WO1996040210A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5622700A (en) 1992-08-21 1997-04-22 Genentech, Inc. Method for treating a LFA-1-mediated disorder
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
WO1997026912A2 (fr) 1996-01-23 1997-07-31 Genentech, Inc. Anticorps dirige contre le cd18 et utilise dans le traitement de l'ictus cerebral
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
WO1998006248A2 (fr) 1996-08-15 1998-02-19 Leukosite, Inc. IMMUNOGLOBINE HUMANISE REAGISSANT AVEC L'INTEGRINE α4β7
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5725856A (en) 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1998023761A1 (fr) 1996-11-27 1998-06-04 Genentech, Inc. ANTICORPS ANTI-CD11a HUMANISES
WO1998024893A2 (fr) 1996-12-03 1998-06-11 Abgenix, Inc. MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES
US5776456A (en) 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1998045331A2 (fr) 1997-04-07 1998-10-15 Genentech, Inc. Anticorps anti-vegf
WO1998051793A1 (fr) 1997-05-15 1998-11-19 Genentech, Inc. RECEPTEUR D'Apo-2
US5849898A (en) 1988-02-25 1998-12-15 The General Hospital Corporation CD40 coding sequences
WO1998056418A1 (fr) 1997-06-13 1998-12-17 Genentech, Inc. Formulation stabilisee renfermant un anticorps
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
WO1999022764A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
WO1999051642A1 (fr) 1998-04-02 1999-10-14 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
WO2000009160A1 (fr) 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Therapies d'association contre les lymphomes malins a cellules b par l'administration d'anticorps anti-cd20
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
WO2000020864A1 (fr) 1998-10-07 2000-04-13 Biocrystal Limited Immunotherapie de l'implication des lymphocytes b dans la progression des tumeurs solides non lymphoides
WO2000027433A1 (fr) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Traitement par anticorps chimere anti-cd20, de patients receveurs de greffes de moelle osseuse ou de cellules souches de sang peripherique
WO2000027428A1 (fr) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Traitement d'affections malignes hematologiques associees a des cellules tumorales en circulation au moyen d'un anticorps chimere anti-cd 20
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
WO2000044788A1 (fr) 1999-01-28 2000-08-03 Idec Pharmaceuticals Corporation Production d'anticorps tetravalents
WO2000067796A1 (fr) 1999-05-07 2000-11-16 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes b
WO2000067795A1 (fr) 1999-05-10 2000-11-16 Immunomedics, Inc. Immunotherapie des manifestations malignes de lymphocytes b au moyen d'anticorps anti-cd22
WO2000075348A1 (fr) 1999-06-08 2000-12-14 Seattle Genetics, Inc. Anticorps anti-cd40 recombinant et utilisations associees
WO2000074718A1 (fr) 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
WO2000076542A1 (fr) 1999-06-11 2000-12-21 Consiglio Nazionale Delle Ricerche Utilisation d'anticorps contre cd20 pour traiter la maladie de rejet du greffon
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO2001003734A1 (fr) 1999-07-12 2001-01-18 Genentech, Inc. Blocage d'une reponse immunitaire a un antigene etranger au moyen d'un antagoniste de liaison a cd20
WO2001010460A1 (fr) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Traitement de lymphomes non hodgkiniens de grade intermediaire ou de haut grade au moyen d'un anticorps anti-cd20
WO2001010462A1 (fr) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20
WO2001010461A1 (fr) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Nouveaux parametres cliniques de determination de la toxicite hematologique avant radioimmunotherapie
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2001013945A1 (fr) 1999-08-23 2001-03-01 Biocrystal Ltd. Methodes et compositions d'immunotherapie destines au traitement des lymphocytes b impliques dans la progression d'un etat pathologique tel que la sclerose en plaques
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
WO2001040309A2 (fr) 1999-10-29 2001-06-07 Genentech, Inc. Compositions a base d'anticorps diriges contre l'antigene de cellules souches de la prostate (psca) et procedes d'utilisation associes
WO2001072333A1 (fr) 2000-03-24 2001-10-04 Chiron Corporation Methodes destinees a traiter un lymphome non hodgkinien au moyen d'une combinaison d'interleukine 2 avec un anticorps anti-cd20
WO2001074388A1 (fr) 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
WO2001077342A1 (fr) 2000-04-11 2001-10-18 Genentech, Inc. Anticorps multivalents et leurs utilisations
WO2001080884A1 (fr) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
WO2001097858A2 (fr) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Traitement de maladies associees aux cellules beta telles que les maladies auto-immunes a caractere malin par combinaison anticorps anti-cd20 froid/anticorps anti-cd22 radiomarque
WO2002004021A1 (fr) 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
WO2002034790A1 (fr) 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Igg3 rituxan r variant et utilisations therapeutiques
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US6410391B1 (en) 1999-07-02 2002-06-25 Infineon Technologies Ag Method for producing an EEPROM memory cell with a trench capacitor
US20020128488A1 (en) 1999-03-12 2002-09-12 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
WO2002079255A1 (fr) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation Anticorps recombinants co-exprimes avec gntiii
US20020197256A1 (en) 2001-04-02 2002-12-26 Genentech, Inc. Combination therapy
WO2002102312A2 (fr) 2001-06-14 2002-12-27 Intermune, Inc. Therapie combinee faisant appel a l'interferon gamma et a des anticorps specifiques des cellules b
WO2003002607A1 (fr) 2001-06-27 2003-01-09 Shawn Shui-On Leung Reduction de l'antigenicite des immunoglobulines par correction de charpente
US20030026801A1 (en) 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US20030068664A1 (en) 2001-09-20 2003-04-10 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
WO2003049694A2 (fr) 2001-12-07 2003-06-19 Chiron Corporation Methodes therapeutiques de traitement d'un lymphome non hodgkinien
WO2003056012A1 (fr) 2001-12-24 2003-07-10 Cancer Research Technology Limited Systeme d'expression stable d'arnsi dans des cellules de mammiferes
US20030139301A1 (en) 2001-10-26 2003-07-24 Gatto Vincent James Dithiocarbamates containing alkylthio and hydroxy substituents
WO2003061694A1 (fr) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression de la reponse immune humorale par des anticorps anti-cd20
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030147885A1 (en) 1992-11-13 2003-08-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO2003064621A2 (fr) 2002-02-01 2003-08-07 Ambion, Inc. Courts fragments d'arn interferant haute activite visant a reduire l'expression de genes cibles
WO2003068821A2 (fr) 2002-02-14 2003-08-21 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2006083971A2 (fr) 2005-02-02 2006-08-10 Genentech, Inc. Anticorps dr5 et utilisations de ceux-ci
US7169908B2 (en) 2003-01-09 2007-01-30 Genentech, Inc. Purification of polypeptides
WO2009006948A1 (fr) 2007-07-12 2009-01-15 Michael Laurence Murphy Emulsion lipidique hydroalcoolique et émulsifiant pour une utilisation dans celle-ci
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US524474A (en) * 1894-08-14 Seed-planter
US670534A (en) * 1900-07-27 1901-03-26 Oliver L Carmical Seeding-machine and fertilizer-distributer.
US1369649A (en) * 1920-01-02 1921-02-22 George A Gieseler Pneumatic conveying mechanism
US2062295A (en) * 1932-11-22 1936-12-01 Niagara Sprayer And Chemical C Crop duster
US2171205A (en) * 1937-08-26 1939-08-29 Louis A Zinke Powder distributing attachment for tractors
US2193738A (en) * 1938-05-21 1940-03-12 Nat Conveyors Co Inc Pneumatic conveyer
US2559183A (en) * 1946-12-10 1951-07-03 Lawton L Barnett Transplanter drill set
US2671690A (en) * 1948-02-21 1954-03-09 Ehrenkrook Karl Von Forced air sprayer and duster
US2937049A (en) * 1949-10-18 1960-05-17 Osawa Hirosaburo Method of and an apparatus for carrying coals out of a vertical shaft with the aid of heavy liquid in the coal mine
US2814531A (en) * 1956-04-27 1957-11-26 Clough Equipment Co Balanced pneumatic conveying systems for pulverulent material
US3207560A (en) * 1962-12-26 1965-09-21 Monsanto Co Unloading device
US3197261A (en) * 1964-03-09 1965-07-27 Simpson Herbert Corp System for feeding and transporting materials
US3386474A (en) * 1965-05-26 1968-06-04 Chemagro Corp Diverter valve for finely divided solids
US3515315A (en) * 1966-01-24 1970-06-02 Kidd Designs Ltd Archie Combined seed and fertilizer drills for agricultural use
US3387895A (en) * 1966-12-29 1968-06-11 Combustion Eng Non-clogging splitter unit for dividing the flow of fluid-conveyed material
FR1558490A (fr) * 1967-12-27 1969-02-28
US3543704A (en) * 1968-08-05 1970-12-01 Deere & Co Seed planter
US3845702A (en) 1970-04-01 1974-11-05 Mies Filter Prod Inc Apparatus for cooking chicken
DE2440888C3 (de) * 1974-08-27 1978-11-23 Waeschle Maschinenfabrik Gmbh, 7980 Ravensburg Anlage zum aufeinanderfolgenden Beschicken mehrerer, hintereinander an eine pneumatische Förderleitung über Abscheider angeschlossener Entnahmestationen mit Schüttgut
US4049494A (en) 1975-09-04 1977-09-20 The United States Of America As Represented By The Secretary Of Agriculture Vaccine production process
US4036408A (en) * 1975-12-24 1977-07-19 Acf Industries, Incorporated Hopper having means for directing blasts of gas to a discharge outlet or the hopper
US4280419A (en) * 1977-03-21 1981-07-28 International Harvester Company Pneumatic system for conveying granular material
US4200412A (en) * 1978-04-20 1980-04-29 Dynamic Air Incorporated Control for pneumatic conveying system
US4264243A (en) * 1979-01-04 1981-04-28 Dundee Cement Company Constant vacuum barge unloading system
US4244522A (en) * 1979-08-31 1981-01-13 Deere & Company Liquid storage and distribution apparatus for agricultural implements
CA1126587A (fr) * 1980-07-11 1982-06-29 Daniel W. Kelm Coupelle doseuse sur semoir
US4413935A (en) * 1981-06-29 1983-11-08 Combustion Engineering, Inc. Flow splitter for dividing a stream of pulverulent material into multiple streams
GB2112506A (en) * 1981-12-30 1983-07-20 Shell Int Research Distributing valve
DE3239897A1 (de) * 1982-10-28 1984-05-03 Trützschler GmbH & Co KG, 4050 Mönchengladbach Verfahren und vorrichtung zur foerderung von faserfoermigen stoffen, insbesondere von in luft schwebend gefoerderten textilen faserflocken bei spinnereivorbereitungsmaschinen
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4562779A (en) * 1984-01-26 1986-01-07 Briggs Manufacturing, Inc. Foldable drill implement
DE3420616A1 (de) * 1984-06-02 1985-12-05 Alb. Klein Gmbh & Co Kg, 5241 Niederfischbach Vorrichtung und verfahren zur steuerung eines schleusvorganges fuer ein haufwerk von schuettgutpartikeln
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4652630A (en) 1985-02-22 1987-03-24 Monsanto Company Method of somatotropin naturation
US5523215A (en) 1985-03-28 1996-06-04 Chiron Corporation Enhanced purification and expression of insoluble recombinant proteins
US4738770A (en) * 1985-11-25 1988-04-19 Cities Service Oil And Gas Corp. Apparatus and method of removal of catalyst blockage from reactor recycle pumps
US4779765A (en) * 1987-04-13 1988-10-25 Deere & Company Fertilizer divider for dual air system
US4793743A (en) * 1987-04-29 1988-12-27 Morris Rod-Weeder Company Ltd. Air seeder purging system
US4872785A (en) * 1988-01-22 1989-10-10 Schrage Timothy L Shut-off means for air-actuated planter
US4843983A (en) * 1988-02-02 1989-07-04 Deere & Company Pneumatic manifold quick coupling
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
DK167639B1 (da) * 1988-11-16 1993-12-06 Kongskilde Maskinfabrik As Maskine til saaning af granuleret materiale
WO1991001367A1 (fr) 1989-07-20 1991-02-07 Bioeng, Inc. Rupture de cellules microbiennes a l'aide de fluides supercritiques et extraction a partir de celles-ci
DE69017793T2 (de) 1989-08-21 1995-08-24 Takeda Chemical Industries Ltd Produktion von menschlichen Nervenwachstumsfaktoren.
US5033914A (en) * 1989-09-29 1991-07-23 Cyclonaire Corporation High efficiency feeder apparatus for pneumatic conveying lines
SG59931A1 (en) 1989-10-16 1999-02-22 Amgen Inc Stem cell factor
GB2237288A (en) 1989-10-18 1991-05-01 Celltech Ltd Amplification of a heterologous gene in recombinant eukaryotic host cells
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
US5069583A (en) * 1990-10-26 1991-12-03 Caldwell Lawrence G Device for changing flow paths in a pneumatic conveying system
EP0511964B1 (fr) 1990-11-23 1997-10-15 Roussel Uclaf PROCEDE DE PREPARATION D'UNE PROTEINE CHOISIE PARMI LES CYTOKINES, COMPORTANT AU MOINS UN PONT DISULFURE INTRAMOLECULAIRE PAR OXYDATION, A UN pH INFERIEUR A 5,0, DE LA PROTEINE RECOMBINANTE REDUITE CORRESPONDANTE
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
US5494381A (en) * 1991-04-11 1996-02-27 The Young Industries, Inc. Apparatus and method for pneumatically conveying bulk materials
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
US5161473A (en) * 1991-05-17 1992-11-10 Deere & Company Seed distribution system and method for a seeding implement
AU3144193A (en) 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5240355A (en) * 1992-05-22 1993-08-31 Nol-Tec Systems, Inc. Dense phase transporter pneumatic conveying system
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
EP0656064B1 (fr) * 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5379706A (en) * 1993-04-07 1995-01-10 Agco Corporation Seed distribution system for planters and drills
AU5752594A (en) * 1993-04-20 1994-11-03 Deere & Company Air separation tube for a pneumatic delivery system
US5407305A (en) * 1993-04-29 1995-04-18 Semco, Inc. Continuous dense phase conveying method utilizing high pressure gas at predetermined gas pressures within a conveying pipe
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
GB9413127D0 (en) 1994-06-30 1994-08-24 Philips Electronics Uk Ltd Data processing apparatus
US5575225A (en) * 1995-02-27 1996-11-19 Unverferth Manufacturing Company, Inc. Air-powered apparatus for filling grain drills and method of using same
DE19513676A1 (de) 1995-04-11 1996-10-17 Behringwerke Ag Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli
WO1996036358A1 (fr) * 1995-05-15 1996-11-21 Cedars-Sinai Medical Center Composition et procede d'inhibition du rejet des greffons heterologues
US5830761A (en) 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
US5813801A (en) * 1996-06-28 1998-09-29 Mac Equipment, Inc. Dense phase particulate conveying system and method with continuous air leakage management
US5749682A (en) * 1996-09-10 1998-05-12 Renfro Corporation Article collection and distribution system
US5912327A (en) 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6365575B1 (en) 1996-10-24 2002-04-02 Vanderbilt University Gene delivery and expression in areas inaccessible to direct protein delivery
US6005081A (en) 1996-11-15 1999-12-21 Genentech, Inc. Purification of recombinant human neurotrophins
DE69739698D1 (de) * 1996-11-27 2010-01-21 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Matrix
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US5927217A (en) * 1997-06-16 1999-07-27 Conserva Pak Seeding Systems Metering particulate material
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US5878679A (en) * 1997-08-18 1999-03-09 Deere & Company Product disconnect for metering device
KR100253916B1 (ko) 1997-12-29 2000-05-01 김충환 사람 인슐린 전구체의 제조방법
IL137177A0 (en) 1998-01-30 2001-07-24 Genesense Technologies Inc Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
PT1071752E (pt) * 1998-04-21 2003-11-28 Micromet Ag Polipeptidos especificos para cd19xcd3 e suas utilizacoes
US6047652A (en) * 1998-05-12 2000-04-11 Case Corporation Seed planter distribution system
NZ528701A (en) 1998-05-15 2005-02-25 Genentech Inc Novel PRO474 polypeptides and nucleic acids encoding same with similarity with dehydrogenase
AU739394B2 (en) 1998-08-27 2001-10-11 Lg Chemical Limited Process for the preparation of active somatotropin from inclusion bodies
NZ511031A (en) * 1998-09-14 2003-11-28 Lars Ostergaard Pedersen A method of producing a functional immunoglobulin superfamily protein
US6298797B1 (en) * 1998-11-05 2001-10-09 Flexi-Coil Ltd. Nurse inductor apparatus for air seeders
EP1048732A1 (fr) * 1999-04-26 2000-11-02 F. Hoffmann-La Roche Ag Procédé de préparation des protéine secretées sous une forme pliée naturelle
DK1200179T3 (da) 1999-07-30 2006-09-25 Genentech Inc Ladede filtreringsmembraner og anvendelser deraf
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
US6872563B1 (en) 1999-10-05 2005-03-29 President And Fellows Of Harvard College Compositions and methods for production of disulfide bond containing proteins in host cells
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2151401A (en) 1999-12-22 2001-07-03 Novo Nordisk A/S Method for extractive refolding of scrambled single-chain polypeptides
US20030009301A1 (en) 2000-05-30 2003-01-09 M.B. Anand Integrated utility meter-reading, billing, payment and usage management system
US7041479B2 (en) * 2000-09-06 2006-05-09 The Board Of Trustess Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
US6548276B2 (en) 2000-09-06 2003-04-15 The Board Of Trustees Of The Leland Stanford Junior University Enhanced in vitro synthesis of active proteins containing disulfide bonds
US20040185535A1 (en) 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
US20070292411A1 (en) * 2000-11-08 2007-12-20 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
WO2002060955A2 (fr) 2001-01-29 2002-08-08 Idec Pharmaceuticals Corporation Anticorps modifies et procedes d'utilisation
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
WO2002068455A2 (fr) 2001-02-23 2002-09-06 Immunex Corporation Augmentation du taux de recuperation de proteines actives
EP1380589A4 (fr) * 2001-03-09 2004-09-01 Chugai Pharmaceutical Co Ltd Methode de purification de proteines
US20030040095A1 (en) 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
CA2447791A1 (fr) 2001-06-13 2002-12-19 Neslihan Delacruz Procedes de mise en culture de cellules animales et production de polypeptides dans des cellules animales
CN1309825C (zh) 2001-10-02 2007-04-11 诺和诺德医疗保健公司 在真核细胞中生产重组蛋白的方法
US20060040348A1 (en) 2001-11-13 2006-02-23 Minmin Qin Methods for producing and purifying recombinant alpha-L-iduronidase
DE60310385T2 (de) 2002-03-23 2007-09-20 Research Development Foundation, Carson City Sekretion von proteinen mit mehreren disulfidbindungen in bakterien und verwendungen davon
US7323553B2 (en) 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US20040029229A1 (en) 2002-05-20 2004-02-12 Reeves Philip J. High level protein expression system
WO2004001056A1 (fr) 2002-06-24 2003-12-31 Dr. Reddy's Laboratories Ltd. Procede de preparation de g-csf
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US7189811B2 (en) 2002-09-06 2007-03-13 National Institute Of Immunology Process for solubilization of recombinant proteins expressed as inclusion body
HUE027134T2 (en) 2002-09-11 2016-10-28 Chugai Pharmaceutical Co Ltd Method for protein purification
WO2004035608A2 (fr) 2002-10-18 2004-04-29 Abgenix, Inc. Systeme et procede de clivage d'anticorps
WO2004067556A1 (fr) 2003-01-31 2004-08-12 Akzo Nobel N.V. Methode d'isolation de proteines dans des conditions anoxiques
JP2007523602A (ja) * 2003-02-06 2007-08-23 マイクロメット アクツィエン ゲゼルシャフト 持続的なｔ細胞応答方法
EP1648940B1 (fr) 2003-07-28 2016-04-27 Genentech, Inc. Reduction de la lixiviation de la proteine a lors de la chromatographie d'affinite sur la proteine a
ES2565077T3 (es) 2003-10-10 2016-03-31 Novo Nordisk Health Care Ag Método para producción en gran escala de un polipéptido en células eucariotas
PL1720979T3 (pl) 2004-03-01 2008-03-31 Ares Trading Sa Zastosowanie podłoża pozbawionego surowicy do hodowli komórkowej do wytwarzania IL-18BP w komórkach ssaków
AU2005286607B2 (en) 2004-09-23 2011-01-27 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
CA2584137A1 (fr) 2004-10-22 2006-06-08 Amgen Inc. Methodes de repliement de polypeptides
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
GB0425534D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
JP2006186521A (ja) 2004-12-27 2006-07-13 Leader Electronics Corp チューナのビットエラーレート（ｂｅｒ）測定の方法および装置
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
WO2007103521A2 (fr) 2006-03-07 2007-09-13 Novartis Ag Prevention du defaut d'incorporation de la norvaline et de la norleucine dans des proteines recombinantes
CA2842959A1 (fr) 2006-09-13 2008-03-20 Abbvie Inc. Ameliorations a la culture de cellules
WO2008127305A2 (fr) 2006-11-01 2008-10-23 Biogen Idec Ma Inc. Procédé d'isolement de biomacromolécules utilisant un faible ph et des cations divalents
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
US8467449B2 (en) * 2007-01-08 2013-06-18 Qualcomm Incorporated CAVLC enhancements for SVC CGS enhancement layer coding
CN101678103A (zh) 2007-03-30 2010-03-24 米迪缪尼股份有限公司 抗体制剂
WO2008135498A2 (fr) 2007-05-04 2008-11-13 Novo Nordisk A/S Prévention contre la dégradation protéique dans des cultures de cellule de mammifère
CA3113365A1 (fr) 2007-07-09 2009-01-15 Genentech, Inc. Prevention de la reduction des liaisons disulfure au cours de la production recombinante de polypeptides
WO2011009625A1 (fr) 2009-07-24 2011-01-27 F. Hoffmann-La Roche Ag Système d'agitateur
KR20160088930A (ko) 2013-12-04 2016-07-26 이뮤노젠 아이엔씨 항체 생산용 조성물 및 항체 생성 방법
EP3877389A4 (fr) 2018-11-05 2022-07-13 Avista Pharma Solutions, Inc. Composés chimiques
IT201900007998A1 (it) 2019-06-04 2020-12-04 Benelli Armi Spa Calcio per arma

Patent Citations (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
EP0003089A1 (fr) 1978-01-06 1979-07-25 Bernard David Séchoir pour feuilles imprimées par sérigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0139383A1 (fr) 1983-08-16 1985-05-02 Zymogenetics, Inc. Méthode pour l'expression de gènes étrangers en Schizosaccharomyces pombe et l'utilisation de ces produits en compositions thérapeutiques, constructions d'ADN et souches transformantes de Schizosaccharomyces pombe utilisables dans une telle méthode et leur préparation
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0183070A2 (fr) 1984-10-30 1986-06-04 Phillips Petroleum Company Transformation de levures du genre Pichia
WO1987000195A1 (fr) 1985-06-28 1987-01-15 Celltech Limited Culture de cellules animales
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0244234A2 (fr) 1986-04-30 1987-11-04 Alko Group Ltd. Transformation de trichoderma
US6120767A (en) 1986-10-27 2000-09-19 Pharmaceutical Royalties, L.L.C. Chimeric antibody with specificity to human B cell surface antigen
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5677180A (en) 1987-01-08 1997-10-14 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5721108A (en) 1987-01-08 1998-02-24 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
EP0307247A2 (fr) 1987-09-11 1989-03-15 Genentech, Inc. Méthode pour cultiver des cellules recombinantes
US5725856A (en) 1988-01-12 1998-03-10 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
EP0330191A2 (fr) 1988-02-25 1989-08-30 The General Hospital Corporation ADN encodant CD40
US5849898A (en) 1988-02-25 1998-12-15 The General Hospital Corporation CD40 coding sequences
EP0332865A2 (fr) 1988-03-17 1989-09-20 American Cyanamid Company Suppression des cellules B des mammifères
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
EP0420937A1 (fr) 1988-06-21 1991-04-10 Genentech Inc Compositions therapeutiques pour le traitement de l'infarctus du myocarde.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US5545807A (en) 1988-10-12 1996-08-13 The Babraham Institute Production of antibodies from transgenic animals
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394538A1 (fr) 1989-04-28 1990-10-31 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh Cellules de levure du genre schwanniomyces
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
WO1991000357A1 (fr) 1989-06-30 1991-01-10 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1993001161A1 (fr) 1991-07-11 1993-01-21 Pfizer Limited Procede de preparation d'intermediaires de sertraline
WO1993004173A1 (fr) 1991-08-14 1993-03-04 Genentech, Inc. Variantes d'immunoglobulines pour des recepteurs specifiques fc epsilon
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
WO1994000136A1 (fr) 1992-06-30 1994-01-06 Oncologix, Inc. COMBINAISON D'ANTICORPS MONOCLONAUX ANTI-erbB-2 ET PROCEDE POUR SON UTILISATION
US5622700A (en) 1992-08-21 1997-04-22 Genentech, Inc. Method for treating a LFA-1-mediated disorder
US6399061B1 (en) 1992-11-13 2002-06-04 Idec Pharmaceutical Corporation Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20030021781A1 (en) 1992-11-13 2003-01-30 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20030082172A1 (en) 1992-11-13 2003-05-01 Idec Pharmaceuticals Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20030095963A1 (en) 1992-11-13 2003-05-22 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma
US5843439A (en) 1992-11-13 1998-12-01 Anderson; Darrell R. Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20030147885A1 (en) 1992-11-13 2003-08-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5776456A (en) 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US20020197255A1 (en) 1992-11-13 2002-12-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1995003770A1 (fr) 1993-08-02 1995-02-09 The Board Of Trustees Of The Leland Stanford Junior University Procedes de regulation de la population des lymphocytes b
US6287537B1 (en) 1993-09-16 2001-09-11 The Regents Of The University Of Michigan Radioimmunotherapy of lymphoma using anti-CD20 antibodies
US6090365A (en) 1993-09-16 2000-07-18 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20 antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5843398A (en) 1993-09-16 1998-12-01 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20 antibodies
US6015542A (en) 1993-09-16 2000-01-18 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20 antibodies
US5714338A (en) 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
WO1995019181A1 (fr) 1994-01-18 1995-07-20 Genentech, Inc. PROCEDE DE TRAITEMENT DE LA PARASITOSE A L'AIDE D'ANTAGONISTES DE L'IgE
WO1995023865A1 (fr) 1994-03-03 1995-09-08 Genentech, Inc. Anticorps monoclonaux anti-il-8 pour le traitement des troubles
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
WO1996027011A1 (fr) 1995-03-01 1996-09-06 Genentech, Inc. Procede d'obtention de polypeptides heteromultimeriques
WO1996030046A1 (fr) 1995-03-30 1996-10-03 Genentech, Inc. Antagonistes de facteurs de croissance des cellules endotheliales vasculaires
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
WO1996040210A1 (fr) 1995-06-07 1996-12-19 Imclone Systems Incorporated Anticorps et fragments d'anticorps inhibant la croissance des tumeurs
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5854067A (en) 1996-01-19 1998-12-29 Board Of Regents, The University Of Texas System Hexokinase inhibitors
WO1997026912A2 (fr) 1996-01-23 1997-07-31 Genentech, Inc. Anticorps dirige contre le cd18 et utilise dans le traitement de l'ictus cerebral
WO1998006248A2 (fr) 1996-08-15 1998-02-19 Leukosite, Inc. IMMUNOGLOBINE HUMANISE REAGISSANT AVEC L'INTEGRINE α4β7
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
WO1998023761A1 (fr) 1996-11-27 1998-06-04 Genentech, Inc. ANTICORPS ANTI-CD11a HUMANISES
WO1998024893A2 (fr) 1996-12-03 1998-06-11 Abgenix, Inc. MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES
WO1998045331A2 (fr) 1997-04-07 1998-10-15 Genentech, Inc. Anticorps anti-vegf
WO1998051793A1 (fr) 1997-05-15 1998-11-19 Genentech, Inc. RECEPTEUR D'Apo-2
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998056418A1 (fr) 1997-06-13 1998-12-17 Genentech, Inc. Formulation stabilisee renfermant un anticorps
WO1998058964A1 (fr) 1997-06-24 1998-12-30 Genentech, Inc. Procedes et compositions concernant des glycoproteines galactosylees
US6368596B1 (en) 1997-07-08 2002-04-09 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
WO1999022764A1 (fr) 1997-10-31 1999-05-14 Genentech, Inc. Compositions renfermant des glycoformes de glycoproteine et methodes afferentes
US20020041847A1 (en) 1998-03-12 2002-04-11 Goldenberg David M. Immunotherapy of malignant and autoimmune disorders in domestic animals using naked antibodies, immunoconjugates and fusion proteins
WO1999051642A1 (fr) 1998-04-02 1999-10-14 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6538124B1 (en) 1998-04-02 2003-03-25 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6455043B1 (en) 1998-08-11 2002-09-24 Idec Pharmaceuticals Corporation Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
WO2000009160A1 (fr) 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Therapies d'association contre les lymphomes malins a cellules b par l'administration d'anticorps anti-cd20
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
WO2000020864A1 (fr) 1998-10-07 2000-04-13 Biocrystal Limited Immunotherapie de l'implication des lymphocytes b dans la progression des tumeurs solides non lymphoides
WO2000027428A1 (fr) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Traitement d'affections malignes hematologiques associees a des cellules tumorales en circulation au moyen d'un anticorps chimere anti-cd 20
WO2000027433A1 (fr) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Traitement par anticorps chimere anti-cd20, de patients receveurs de greffes de moelle osseuse ou de cellules souches de sang peripherique
WO2000042072A2 (fr) 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
WO2000044788A1 (fr) 1999-01-28 2000-08-03 Idec Pharmaceuticals Corporation Production d'anticorps tetravalents
US20020128488A1 (en) 1999-03-12 2002-09-12 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
WO2000067796A1 (fr) 1999-05-07 2000-11-16 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes b
WO2000067795A1 (fr) 1999-05-10 2000-11-16 Immunomedics, Inc. Immunotherapie des manifestations malignes de lymphocytes b au moyen d'anticorps anti-cd22
WO2000075348A1 (fr) 1999-06-08 2000-12-14 Seattle Genetics, Inc. Anticorps anti-cd40 recombinant et utilisations associees
WO2000074718A1 (fr) 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
WO2000076542A1 (fr) 1999-06-11 2000-12-21 Consiglio Nazionale Delle Ricerche Utilisation d'anticorps contre cd20 pour traiter la maladie de rejet du greffon
US6410391B1 (en) 1999-07-02 2002-06-25 Infineon Technologies Ag Method for producing an EEPROM memory cell with a trench capacitor
WO2001003734A1 (fr) 1999-07-12 2001-01-18 Genentech, Inc. Blocage d'une reponse immunitaire a un antigene etranger au moyen d'un antagoniste de liaison a cd20
WO2001010461A1 (fr) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Nouveaux parametres cliniques de determination de la toxicite hematologique avant radioimmunotherapie
WO2001010460A1 (fr) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Traitement de lymphomes non hodgkiniens de grade intermediaire ou de haut grade au moyen d'un anticorps anti-cd20
WO2001010462A1 (fr) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Traitement pour patients atteint d'un lymphome different de la maladie de hodgkins et qui touche la moelle osseuse, avec des anticorps anti-cd20
WO2001013945A1 (fr) 1999-08-23 2001-03-01 Biocrystal Ltd. Methodes et compositions d'immunotherapie destines au traitement des lymphocytes b impliques dans la progression d'un etat pathologique tel que la sclerose en plaques
WO2001040309A2 (fr) 1999-10-29 2001-06-07 Genentech, Inc. Compositions a base d'anticorps diriges contre l'antigene de cellules souches de la prostate (psca) et procedes d'utilisation associes
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20030185796A1 (en) 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
WO2001072333A1 (fr) 2000-03-24 2001-10-04 Chiron Corporation Methodes destinees a traiter un lymphome non hodgkinien au moyen d'une combinaison d'interleukine 2 avec un anticorps anti-cd20
US20020012665A1 (en) 2000-03-31 2002-01-31 Nabil Hanna Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
WO2001074388A1 (fr) 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Utilisation combinee d'anticorps ou d'antagonistes anti-cytokine et d'anti-cd20 pour le traitement du lymphome b
WO2001077342A1 (fr) 2000-04-11 2001-10-18 Genentech, Inc. Anticorps multivalents et leurs utilisations
US20020004587A1 (en) 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
US20020009444A1 (en) 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
WO2001080884A1 (fr) 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
WO2001097858A2 (fr) 2000-06-20 2001-12-27 Idec Pharmaceuticals Corporation Traitement de maladies associees aux cellules beta telles que les maladies auto-immunes a caractere malin par combinaison anticorps anti-cd20 froid/anticorps anti-cd22 radiomarque
US20030026801A1 (en) 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer
WO2002004021A1 (fr) 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
WO2002034790A1 (fr) 2000-10-20 2002-05-02 Idec Pharmaceuticals Corporation Igg3 rituxan r variant et utilisations therapeutiques
WO2002079255A1 (fr) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation Anticorps recombinants co-exprimes avec gntiii
US20020197256A1 (en) 2001-04-02 2002-12-26 Genentech, Inc. Combination therapy
WO2003061694A1 (fr) 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression de la reponse immune humorale par des anticorps anti-cd20
WO2002102312A2 (fr) 2001-06-14 2002-12-27 Intermune, Inc. Therapie combinee faisant appel a l'interferon gamma et a des anticorps specifiques des cellules b
WO2003002607A1 (fr) 2001-06-27 2003-01-09 Shawn Shui-On Leung Reduction de l'antigenicite des immunoglobulines par correction de charpente
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030068664A1 (en) 2001-09-20 2003-04-10 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20030139301A1 (en) 2001-10-26 2003-07-24 Gatto Vincent James Dithiocarbamates containing alkylthio and hydroxy substituents
US20030103971A1 (en) 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
WO2003049694A2 (fr) 2001-12-07 2003-06-19 Chiron Corporation Methodes therapeutiques de traitement d'un lymphome non hodgkinien
WO2003056012A1 (fr) 2001-12-24 2003-07-10 Cancer Research Technology Limited Systeme d'expression stable d'arnsi dans des cellules de mammiferes
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003064621A2 (fr) 2002-02-01 2003-08-07 Ambion, Inc. Courts fragments d'arn interferant haute activite visant a reduire l'expression de genes cibles
WO2003068821A2 (fr) 2002-02-14 2003-08-21 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
US20030219433A1 (en) 2002-02-14 2003-11-27 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20030219818A1 (en) 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US7169908B2 (en) 2003-01-09 2007-01-30 Genentech, Inc. Purification of polypeptides
WO2006083971A2 (fr) 2005-02-02 2006-08-10 Genentech, Inc. Anticorps dr5 et utilisations de ceux-ci
WO2009006948A1 (fr) 2007-07-12 2009-01-15 Michael Laurence Murphy Emulsion lipidique hydroalcoolique et émulsifiant pour une utilisation dans celle-ci
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Non-Patent Citations (138)

* Cited by examiner, † Cited by third party
Title
"Annual Review of Immunology", ADVANCES IN IMMUNOLOGY
ABBAS ET AL.: "Cellular and Mol. Immunology", 2000
ARTEAGA ET AL., CANCER RES., vol. 54, 1994, pages 3758 - 3765
ARUFFO ET AL., CELL, vol. 61, 1990, pages 1303 - 1313
BABSON, A.L.BABSON, S.R.: "Kinetic Colorimetric Measurement of Serum Lactate Dehydrogenase Activity", CLIN. CHEM., vol. 19, 1973, pages 766 - 769, XP009119838
BACUS ET AL., MOLECULAR CARCINOGENESIS, vol. 3, 1990, pages 350 - 362
BALLANCE ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 112, 1983, pages 284 - 289
BARBAS ET AL., PROC NAT. ACAD. SCI. USA, vol. 91, 1994, pages 3809 - 3813
BARNESSATO1980, ANAL. BIOCHEM., vol. 102, pages 255
BASELGA ET AL., J. CLIN. ONCOL., vol. 14, 1996, pages 737 - 744
BASS ET AL., PROTEINS, vol. 8, 1990, pages 309 - 314
BEACHNURSE, NATURE, vol. 290, 1981, pages 140 - 681
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
BRODEUR ET AL.: "Monoclonal Antibody Production Techniques and Applications", vol. 2, 1987, AMERICAN SOCIETY FOR MICROBIOLOGY, pages: 1190 - 1219
BRUGGEMANN ET AL., YEAR IN IMMUNOL, vol. 7, 1993, pages 33
BRUGGERMANN ET AL., YEAR IN IMMUNO., vol. 7, 1993, pages 33
C. ANTHONY, THE BIOCHEMISTRY OF METHYLOTROPHS, vol. 269, 1982
CARTER ET AL., BIO/TECHNOLOGY, vol. 10, 1992, pages 163 - 167
CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 - 4289
CASE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 5259 - 5263
CHADERJIAN ET AL., BIOTECHNOL. PROG., vol. 21, no. 2, 2005, pages 550 - 3
CHADERJIAN, W.B., CHIN, E.T., HARRIS, R.J., AND ETCHEVERRY, T.M.: "Effect of copper sulfate on performance of a serum-free CIIO cell culture process and the level of free thiol in the recombinant antibody expressed", BIOTECHNOL. PROG., vol. 21, 2005, pages 550 - 553
CHOY ET AL., ARTHRITIS RHEUM, vol. 39, no. 1, 1996, pages 52 - 56
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
DANA C. ANDERSEN ET AL.: "Production Technologies for Monoclonal Antibodies and Their Fragments", CURRENT OPINION IN BIOTECHNOLOGY, vol. 15, 2004, pages 456 - 462, XP004588033, DOI: 10.1016/j.copbio.2004.08.002
DEMIDEM ET AL., CANCER CHEMOTHERAPY & RADIOPHARMACEUTICALS, vol. 12, no. 3, 1997, pages 177 - 186
DEVITA ET AL.: "Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis", ARTHRITIS & RHEUMATISM, vol. 46, 2002, pages 2029 - 2033
DHAINAUT ET AL., CRIT. CARE MED., vol. 23, no. 9, 1995, pages 1461 - 1469
DUCHOSAL ET AL., NATURE, vol. 355, 1992, pages 258
EDWARDS ET AL.: "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders", BIOCHEM. SOC. TRANS., vol. 30, no. 4, 2002, pages 824 - 828, XP002306250, DOI: 10.1042/BST0300824
EDWARDS ET AL.: "Efficacy and safety of Rituximab, a B-cell targeted chimeric monoclonal antibody: A randomized, placebo controlled trial in patients with rheumatoid arthritis", ARTHRITIS & RHEUMATISM, vol. 46, no. 9, 2002, pages S197
EDWARDSCAMBRIDGE: "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes", RHEUMATOLOGY, vol. 40, 2001, pages 205 - 211, XP002348931, DOI: 10.1093/rheumatology/40.2.205
FAHRNER ET AL., BIOTECHNOL. GENET. ENG. REV., vol. 18, 2001, pages 301 - 27
FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472
FISHWILD ET AL., NATURE BIOTECHNOL., vol. 14, 1996, pages 826 - 851
FLAMWALLACE, METH. IN ENZ., vol. 58, 1979, pages 44
FLEER ET AL., BIO/TECHNOLOGY, vol. 2, 1991, pages 968 - 975
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 1 03
GORDON G.MACKOW M.C.LEVY H.R.: "On the mechanism of interaction of steroids with human glucose 6-phosphate dehydrogenase", ARCH. BIOCHEM. BIOPHYS., vol. 318, 1995, pages 25 - 29, XP055514709, DOI: 10.1006/abbi.1995.1199
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59
GRAZIANO ET AL., J. IMMUNOL., vol. 155, no. 10, 1995, pages 4996 - 5002
GROMER S.URIG S.BECKER K.: "TheTrx System - From Science to Clinic", MEDICINAL RESEARCH REVIEWS, vol. 24, 2004, pages 40 - 89, XP002694209, DOI: 10.1002/med.10051
GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368
HAMIS, Σ3IOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038
HAMMES G.G.KOCHAVI D.: "Studies of the Enzyme Hexokinase. I. Steady State Kinetics at pH 8", J. AM. CHEM. SOC., vol. 84, 1962, pages 2069 - 2073
HAMMES G.G.KOCHAVI D.: "Studies of the Enzyme Hexokinase. III. The Role of the Metal Ion", J. AM. CHEM. SOC., vol. 84, 1962, pages 2076 - 2079
HANCOCK ET AL., CANCER RES., vol. 51, 1991, pages 4575 - 4580
HARWERTH ET AL., J. BIOL. CHEM., vol. 267, 1992, pages 15160 - 15167
HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896
HIDASHIDA ET AL.: "Treatment of DMARD-Refractory rheumatoid arthritis with rituximab", PRESENTED AT THE ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, 2002
HOOGENBOOM ET AL., MOL. IMMUNOL., vol. 28, 1991, pages 1027 - 1037
HOURMANT ET AL., TRANSPLANTATION, vol. 113, 1994, pages 377 - 380
HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
ILURLEGROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433
JAKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
JOHANSSON C., LILLIG C.H., AND HOLMGREN A.: "Human Mitochondrial Glutaredoxin Reduces S-Glutathionylated Proteins with High Affinity Accepting Electrons from Either Glutathione or Thioredoxin Reductase", J. BIOL. CHEM., vol. 279, 2004, pages 7537 - 7543, XP055514721, DOI: 10.1074/jbc.M312719200
JOHN C. JOLY ET AL.: "Overexpression of Eschericia coli Oxidoreductases Increases Recombinant Insulin-like Growth Factor-I Accumulation", PROC. NATL. ACAD. SCI. USA, vol. 95, March 1998 (1998-03-01), pages 2773 - 2777
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JUWEID ET AL., CANCER RES, vol. 55, 1995, pages 5899s - 5907s
KASPRZYK ET AL., CANCER RESEARCH, vol. 52, 1992, pages 2771 - 2776
KELLYHYNES, EMBO J., vol. 4, 1985, pages 475 - 479
KIM ET AL., GROWTH FACTORS, vol. 7, 1992, pages 53 - 64
KIPRIYANOVLITTLE, MOLECULAR BIOTECHNOLOGY, vol. 12, 1999, pages 173 - 201
KIRKPATRICK D.L.KUPERUS M.DOWDESWELL M.POTIER N.DONALD L.J.KUNKEL M.BERGGREN M.ANGULO M.POWIS G.: "Mechanisms of inhibition of the Trx growth factor system by antitumor 2-imidazolyl disulfides", BIOCHEM. PHARMACOL., vol. 55, 1998, pages 987 - 994, XP002979943, DOI: 10.1016/S0006-2952(97)00597-2
KIRKPATRICK D.L.WATSON S.KUNKEL M.FLETCHER S.ULHAQ S.POWIS G.: "Parallel syntheses of disulfide inhibitors of the Trx redox system as potential antitumor agents", ANTICANCER DRUG DES, vol. 14, 1999, pages 421 - 432
KLAPPER ET AL., ONCOGENE, vol. 14, 1997, pages 2099 - 2109
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001
LAURA C. SIMMONS ET AL.: "Expression of Full-length Immunoglobulins in Escherichia coli: Rapid and Efficient Production of Aglycosylated Antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 263, 2002, pages 133 - 147
LEANDRO ET AL.: "An open study of B lymphocyte depletion in systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, vol. 46, no. 1, 2002, pages 2673 - 2677, XP002378313, DOI: 10.1002/art.10541
LEANDRO ET AL.: "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion", ANN RHEUM DIS, vol. 61, 2002, pages 833 - 888
LEANDRO ET AL.: "Lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response", ARTHRITIS & RHEUMATISM, vol. 44, no. 9, 2001, pages S370
LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132
LEGRAND, C.BOUR, J.M.JACOB, C.CAPIAUMONT J.MARTIAL, A.MARC, A.WUDTKE, M.KRETZMER, G.DEMANGEL, C.DUVAL, D.: "Lactate Dehydrogenase (LDH) Activity of the Number of Dead Cells in the Medium of Cultured Eukaryotic Cells as Marker", J. BIOTECHNOL., vol. 25, 1992, pages 231 - 243, XP024346496, DOI: 10.1016/0168-1656(92)90158-6
LEHRNBECHER ET AL., BLOOD, vol. 94, 1999, pages 4220
LEVINEPESTRONK: "IgM antibody-related polyneuropathies: Σ3-cell depletion chemotherapy using Rituximab", NEUROLOGY, vol. 52, 1999, pages 1701 - 1704, XP000942610
LI ET AL.: "Nature Biology", 22 January 2006, article "Optimization of humanized IgGs in glycoengineered Pichia pastoris"
LITTON ET AL., EUR J. IMMUNOL., vol. 26, no. 1, 1996, pages 1 - 9
LLOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381 - 597
LONBERG ET AL., NATURE, vol. 368, 1994, pages 812 - 813
LONBERGHUSZAR, INTERN. REV. IMMUNOL., vol. 13, 1995, pages 65 - 93
LORENZ ET AL., J. IMMUNOL., vol. 156, no. 4, 1996, pages 1646 - 1653
LOUVENCOURT ET AL., J. BACTERIOL., vol. 737, 1983
MALONEY ET AL., BLOOD, vol. 88, no. 10, 1996, pages 637a
MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783
MATHER ET AL., ANNALS N. Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251
MATTHEWS, R: "Medical Heretics", NEW SCIENTIST, 7 April 2001 (2001-04-07)
MCCAFFERTY ET AL., NATURE, vol. 348, 1999, pages 552 - 554
MCDONALD, M.R.: "Methods in Enzymology", vol. 1, 1955, ACADEMIC PRESS, article "Yeast Hexokinase : ATP + Hexose --> Hexose-6-phosphate + ADP", pages: 269 - 276
MCKENZIE ET AL., ONCOGENE, vol. 4, 1989, pages 543 - 548
MICHAEL W. LAIRD ET AL.: "Optimization of BLyS Production and Purification from Eschericia coli", PROTEIN EXPRESSION AND PURIFICATION, vol. 39, 2005, pages 237 - 246
MILHAUSEN, M.LEVY, H.R.: "Evidence for an Essential Lysine in G6PD from Leuconostoc mesenteroides", EUR. J. BIOCHEM., vol. 50, 1975, pages 453 - 461, XP055515265
MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539
MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, vol. 24, 1992, pages 107 - 117
MORRISON ET AL., PROC. NATL ACAD. SCI. USA, vol. 81, 1984, pages 6851
NIWA R. ET AL., CANCER RES., vol. 64, no. 6, 2004, pages 2127 - 2133
PAUL H. BESSETTE ET AL.: "Folding of Proteins with Multiple Disulfide Bonds in the Escherichia coli cytoplasm", PROC. NATL. ACAD. SCI., vol. 96, no. 24, 1999, pages 13703 - 08, XP002233564, DOI: 10.1073/pnas.96.24.13703
PEROTTAABUEL: "Response of chronic relapsing ITP of 10 years duration to Rituximab", ABSTRACT # 3360 BLOOD, vol. 10, no. 1, 1998, pages 88B
PLEASANTS, J.C.GUO, W.RABENSTEIN, D.L.: "A comparative study of the kinetics of selenol/diselenide and thiol/disulfide exchange reactions", J. AM. CHEM. SOC., vol. 111, 1989, pages 6553 - 6558, XP055518635
PRESTA ET AL., J. IMMNOL., vol. 151, 1993, pages 2623
PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296 - 2632
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
REFF ET AL., BLOOD, vol. 83, no. 2, 1994, pages 435 - 445
RICHMAN ET AL., CANCER RES., vol. 55, no. 23, 1995, pages 5916s - 5920s
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
SARWAL ET AL., N. ENG. J. MED., vol. 349, no. 2, 10 July 2003 (2003-07-10), pages 125 - 138
SCHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155
SHALABY ET AL., J. EXP. MED., vol. 175, 1992, pages 217 - 225
SHI Y., TRENDS IN GENETICS, vol. 19, no. 1, 2003, pages 9 - 12
SHINKAWA ET AL., J BIO. CHEM., vol. 278, no. 5, 2003, pages 3466 - 347
SIDHU ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093
SOLS, A.DELAFUENTE, G.VILLAR-PALASI, C.ASENSIO, C.: "Substrate Specificity and Some Other Properties of Bakers' Yeast Hexokinase", BIOCHIM BIOPHYS ACTA, vol. 30, 1958, pages 92 - 101, XP023378283, DOI: 10.1016/0006-3002(58)90245-2
SREEKRISHNA ET AL., J. BASIC MICROBIOL., vol. 28, 1988, pages 265 - 278
ST JOHN ET AL., CHEST, vol. 103, 1993, pages 932
STAMENKOVIC ET AL., CELL, vol. 66, 1991, pages 1133 - 1144
STANCOVSKI ET AL., PNAS (USA), vol. 88, 1991, pages 8691 - 8695
STASHI ET AL.: "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idopathic thrombocytopenic purpura", BLOOD, vol. 98, no. 4, 2001, pages 952 - 957
STEPPE ET AL., TRANSPLANT INTL, vol. 4, 1991, pages 3 - 7
TAGLIABUE ET AL., INT. J. CANCER, vol. 47, 1991, pages 933 - 937
TILBURN ET AL., GENE, vol. 26, 1983, pages 205 - 221
TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659
TUSCANO, J: "Successful treatment of Infliximab-refractory rheumatoid arthritis with rituximab", ANNUAL SCIENTIFIC MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, 2002
TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
VAN DEN BERG ET AL., BIO/TECHNOLOGY, vol. 8, 1990, pages 135
VASWANIHAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115
VAUGHAN ET AL., NATURE BIOTECH, vol. 14, 1996, pages 309
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536
WATERHOUSE ET AL., NUC. ACIDS. RES., vol. 21, 1993, pages 2265 - 2266
WHITESIDES, G.M.LILBURN, J.E.SZAJEWSKI, R.P.: "Rates of thioldisulfide interchange reactions between mono- and dithiols and Ellman's reagent", J. ORG. CHEM., vol. 42, 1977, pages 332 - 338
WIPF P.HOPKINS T.D.LUNG J.K.RODRIGUEZ S.BIRMINGHAM A.SOUTHWICK E.C.LAZO J.S.POWIS G: "New inhibitors of the Trx-TrxR system based on a naphthoquinone spiroketal natural product lead", BIOORG. MED. CHEM. LETT., vol. 11, 2001, pages 2637 - 2641
XU ET AL., INT. J. CANCER, vol. 53, 1993, pages 401 - 408
YARIV MAZOR ET AL.: "Isolation of Engineered, Full-length Antibodies from Libraries Expressed in Escherichia coli", NATURE BIOTECH, vol. 25, 1 June 2007 (2007-06-01), pages 563 - 565, XP002488027, DOI: 10.1038/nbt1296
YELTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 1470 - 1474
ZAPATA ET AL., PROTEIN ENG, vol. 8, no. 10, 1995, pages 1057 - 1062

Also Published As

Publication number Publication date
DE17196350T1 (de) 2018-12-27
LT3597659T (lt) 2023-05-10
US20230383004A1 (en) 2023-11-30
EP2188302A2 (fr) 2010-05-26
US8574869B2 (en) 2013-11-05
SG10201913363VA (en) 2020-03-30
US10906986B2 (en) 2021-02-02
SG10201406411XA (en) 2014-11-27
ES2751022T3 (es) 2020-03-30
US11987638B1 (en) 2024-05-21
EP4245766A9 (fr) 2024-01-24
KR20150042305A (ko) 2015-04-20
US20210095040A1 (en) 2021-04-01
EP4219522A2 (fr) 2023-08-02
CN107090017A (zh) 2017-08-25
US20240150486A1 (en) 2024-05-09
US20190135935A1 (en) 2019-05-09
KR20190140090A (ko) 2019-12-18
JP2020105180A (ja) 2020-07-09
CN101932591B (zh) 2018-02-16
JP2010533192A (ja) 2010-10-21
US20210188993A1 (en) 2021-06-24
LT3327026T (lt) 2019-11-11
FI3597659T3 (fi) 2023-05-03
AU2013203411C1 (en) 2017-01-19
KR102262298B1 (ko) 2021-06-07
TWI574974B (zh) 2017-03-21
IL237755B (en) 2020-02-27
TR201802088T4 (tr) 2018-03-21
HRP20180673T1 (hr) 2018-06-01
JP2017046706A (ja) 2017-03-09
WO2009009523A2 (fr) 2009-01-15
US20200347145A1 (en) 2020-11-05
JP2014129358A (ja) 2014-07-10
EP3597659A1 (fr) 2020-01-22
ES2941738T3 (es) 2023-05-25
HUE061746T2 (hu) 2023-08-28
HRP20230461T3 (hr) 2023-07-21
US11999791B2 (en) 2024-06-04
US11639395B2 (en) 2023-05-02
EP4365189A3 (fr) 2024-08-14
KR20210021144A (ko) 2021-02-24
CN112480255A (zh) 2021-03-12
MX2010000196A (es) 2010-04-21
US20230365704A1 (en) 2023-11-16
EP2586788B1 (fr) 2017-11-29
ES2655474T3 (es) 2018-02-20
US10808037B1 (en) 2020-10-20
JP6030079B2 (ja) 2016-11-24
EP3327026B1 (fr) 2019-08-21
CA2691692A1 (fr) 2009-01-15
HUE037633T2 (hu) 2018-09-28
IL246683A0 (en) 2016-08-31
BRPI0812603B1 (pt) 2021-06-29
EP3327026A1 (fr) 2018-05-30
SI2188302T1 (en) 2018-07-31
US12098211B2 (en) 2024-09-24
SI2586788T1 (en) 2018-07-31
AU2013203411B9 (en) 2017-02-09
JP6721621B2 (ja) 2020-07-15
HUE046992T2 (hu) 2020-04-28
US20240301080A1 (en) 2024-09-12
IL272591A (en) 2020-03-31
KR101851580B1 (ko) 2018-04-25
TW202124409A (zh) 2021-07-01
EP2188302B1 (fr) 2017-11-01
US20240158527A1 (en) 2024-05-16
AU2013203411B2 (en) 2016-09-08
DK3597659T3 (da) 2023-04-03
CA2691692C (fr) 2021-05-18
IL237755A0 (en) 2015-05-31
IL202934B (en) 2019-05-30
JP5687057B2 (ja) 2015-03-18
US20240132612A1 (en) 2024-04-25
PL3597659T3 (pl) 2023-07-10
PT3597659T (pt) 2023-04-04
US20140128575A1 (en) 2014-05-08
US20200317801A1 (en) 2020-10-08
EP4335863A3 (fr) 2024-07-24
SI3597659T1 (sl) 2023-04-28
AU2013203411C9 (en) 2017-02-09
US11976127B1 (en) 2024-05-07
EP2586788A1 (fr) 2013-05-01
US20090053786A1 (en) 2009-02-26
PT3327026T (pt) 2019-10-30
CA3113365A1 (fr) 2009-01-15
AU2008275229B2 (en) 2014-11-06
HRP20191905T1 (hr) 2020-01-24
CN101932591A (zh) 2010-12-29
PL2586788T3 (pl) 2018-05-30
IL259860A (en) 2018-07-31
TWI666217B (zh) 2019-07-21
SI3327026T1 (sl) 2019-11-29
AU2013203411A1 (en) 2013-05-02
TW201942127A (zh) 2019-11-01
TW201713679A (zh) 2017-04-16
BRPI0812603A2 (pt) 2015-03-03
KR20100061442A (ko) 2010-06-07
PL2188302T3 (pl) 2018-04-30
CN112480255B (zh) 2024-09-27
KR20180042457A (ko) 2018-04-25
DK3597659T5 (da) 2024-09-02
EP4245766A3 (fr) 2024-01-17
TW200914462A (en) 2009-04-01
EP4365189A2 (fr) 2024-05-08
HUE037162T2 (hu) 2018-08-28
JP2018111698A (ja) 2018-07-19
TWI702225B (zh) 2020-08-21
US11078294B2 (en) 2021-08-03
WO2009009523A3 (fr) 2009-05-14
EP4219522A3 (fr) 2023-09-20
US20170313780A1 (en) 2017-11-02
US20130017598A1 (en) 2013-01-17
EP3597659B1 (fr) 2023-03-01
US11987637B1 (en) 2024-05-21
ES2659829T3 (es) 2018-03-19
IL237754A0 (en) 2015-05-31
US10759866B2 (en) 2020-09-01
AU2008275229A1 (en) 2009-01-15
KR20160105539A (ko) 2016-09-06
KR101643514B1 (ko) 2016-07-27
PL3327026T3 (pl) 2020-02-28
DK3327026T3 (da) 2019-10-28
EP4335863A2 (fr) 2024-03-13
MX354993B (es) 2018-03-28
SG10202005450PA (en) 2020-07-29
KR102055873B1 (ko) 2019-12-13

Similar Documents

Publication Publication Date Title
US11987638B1 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
US12145997B2 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides
AU2018201301B2 (en) Prevention of disulfide bond reduction during recombinant production of polypeptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2188302

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2586788

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3327026

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3597659

Country of ref document: EP

Kind code of ref document: P

Ref document number: 4219522

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0014000000

Ipc: C07K0001000000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/00 20060101ALI20231214BHEP

Ipc: C07K 1/00 20060101AFI20231214BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240131

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40102746

Country of ref document: HK